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ABSTRACT 
Valvular heart diseases lead to over 290,000 heart valve replacements worldwide 
each year, and approximately half of these involve replacement with a bioprosthetic heart 
valve (BHV) [43].  BHVs exhibit excellent hemocompatibility, but suffer from 
inadequate long-term durability with most adult implanted valves failing within 12 to 15 
years after implantation [62].  Although this may be adequate for some individuals, BHV 
implantation may be contraindicated in younger individuals to avoid reoperation.  Even 
in elder recipients, valve dysfunction can still cause death or reoperation that could be 
avoided with increased BHV durability.  Therefore, investigation into methods of 
increasing BHV durability can not only improve the quality of life for BHV recipients, 
but widen the accessible patient demographic as well. 
All BHVs are currently treated with glutaraldehyde, which is used to stabilize 
collagen through crosslinking as well as reduce tissue immunogenicity.  However, 
glutaraldehyde crosslinking potentiates BHV calcification and also causes undesirable 
alterations to tissue properties that are conducive to structural degeneration [5,78,143].  
Considering that calcification and structural degradation are the foremost causes of BHV 
failure, there has been interest in alternative, non-glutaraldehyde fixation methods [5]. 
One phenomenon that can contribute to structural degeneration is the loss of 
glycosaminoglycans (GAGs) from cuspal tissue [15,19].  GAGs are large highly 
hydrophilic molecules that form a gel-like sheet within the center layer of valve cusps.  
This layer aids in stress absorption and reduction of shearing between the other tissue 
layers [18].  GAGs lack the amine functionalities to be crosslinked by glutaraldehyde and 
under current fixation methods are lost during preparation, in vivo implantation and 
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storage [18,19,75].  Carbodiimide crosslinking with EDC and NHS reacts with available 
carboxyl groups in addition to amine groups allowing for the crosslinking of both GAGs 
and collagen.  These crosslinks may aid in GAG preservation and thereby contribute to 
improved mechanical function.  However, it has been shown that crosslinking alone is 
not sufficient to fully preserve GAGs, as they are still prone to loss through enzymatic 
degradation [132].   
Neomycin, a hyaluronidase inhibitor, has been shown previously to prevent the 
enzymatic degradation of GAGs [133].  Neomycin also contains amine functionalities 
that enable stable incorporation into carbodiimide-initiated crosslinks.  This study 
investigates the effects of carbodiimide crosslinking in combination with neomycin on 
the stability of structural proteins, GAG preservation, calcification, and biomechanical 
properties.   
The incorporation of neomycin into EDC, and NHS fixation (NEN) was found to 
improve GAG retention, fully preventing loss during storage, implantation, and direct 
enzymatic digestion.  Additionally, the use of neomycin enhanced the elastin and 
collagen stability of EDC and NHS crosslinking alone (EDC).  When compared to 
glutaraldehyde crosslinked tissues (GLUT), NEN treated tissues demonstrated 
comparable collagen and elastin stability but far superior GAG retention.  EDC and NEN 
groups also displayed reduced stiffness and increased extensibility when compared to 
GLUT crosslinked tissues.  These results suggest that NEN fixation and resulting GAG 
preservation may improve the mechanics of BHV tissues.  In doing so, tissue stress and 
loads that occur during function may be reduced, preventing the onset of collagen 
damage and increasing the lifespan of BHVs. 
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1. LITERATURE REVIEW 
1.1. Anatomy of the Heart 
The human heart is a physiological pump that ensures continuous transport of 
blood throughout the body for the entire lifetime of an individual.  It contains four 
distinct chambers consisting of two ventricles and two atria, both left and right.  The right 
chambers of the heart contribute to the body’s pulmonary circulation while the left side of 
the heart provides systemic circulation.  Blood is driven through the body by pressure 
gradients that have varying intensities in different sections of the heart [1-3].  Due to the 
much greater resistance offered by systemic circulation, mean pressures are higher in the 
left side of the heart where average values are approximately 80 mm Hg during diastole 
and 120 mm Hg in systole upon entry into the aorta.  Pressures in the right side are much 
milder amounting only to values of around 10 - 25 mm Hg in the pulmonary artery [1,2]. 
Blood transport in the heart begins at the right atrium.  Deoxygenated blood is 
received from the inferior and superior vena cava before passing blood into the right 
ventricle for delivery to the lungs using the pulmonary arteries.  Oxygenated blood from 
the lungs is then transported to the left atrium through the pulmonary veins and lastly into 
the left ventricle, which distributes blood to the rest of the body via the aorta.  The heart 
itself is supplied with blood by the coronary arteries that originate in the left and right 
aortic sinus at the aortic root.  Deoxygenated blood from the heart collects in the coronary 
sinus and empties into the right atrium to again to be cycled through the heart [1-3]. 
In order to ensure efficient and constant forward blood motion throughout the 
heart, there are four valves in place that function to prevent backflow.  These valves are 
composed of connective tissue formed into “cusps” or “leaflets” that open and close to 
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regulate blood flow [1-3].  These valves are located at the entrance and exit of each 
ventricle and are each attached at their base to the cardiac skeleton.  The cardiac skeleton 
separates the atria from the ventricles and although it is not a true skeleton, is composed 
of dense connective tissue and provides vital structural support to the heart.  The fibrous 
rings that compose the cardiac skeleton serve as attachment points for the heart valves, 
muscular fibers, and major vessels in the heart.  The attachment point for the heart valve 
cusps on the cardiac skeleton is known as the annulus, which is an important reference 
point when concerning native and artificial heart valve position [2]. 
Two of the four valves located in the heart are known as the atrioventricular (AV) 
valves, while the other two are identified as the semilunar valves [1-3].  Under normal 
circumstances, these valves function constantly throughout the approximately 3 billion 
cardiac cycles that occur in a single lifetime [4].  The AV valves separate each of the atria 
from their respective ventricles and prevent backflow from the ventricles during systole.  
The right AV valve is commonly known as the tricuspid valve, while the left is called the 
mitral valve [1-3].  These valves are anchored to the heart wall by thread-like structures 
called chordae tendineae.  These collagen-based structures are attached to the heart wall 
at the papillary muscles, which contract during systole in order to pull the chordae 
tendineae taut and prevent over closure and inversion of the AV valves [1-2].  The 
closure of these valves is associated with the first heart sound, coined “lubb”, while the 
second heart sound results from closure of the two remaining heart valves after 
ventricular systole and is termed “dubb”.  These other two valves, the semilunar valves, 
are named the pulmonary and aortic valves.  They lead into the pulmonary arteries and 
aorta respectively and prevent retrograde flow into the ventricles [1-3]. 
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Figure 1. Cross-section of Heart and Blood Circulation Diagram (Adapted from [2]). 
 
1.1.1. Heart Valves 
Heart valves are composed of cusps or leaflets that open and close to regulate 
blood flow.  Each valve in the heart has three cusps that seal together during closure 
except for the mitral valve, which has only two.  Although the basic function of heart 
valves is simple, the role they fill is quite demanding.  Despite being in the extremely 
volatile environment of the bloodstream, each valve must exhibit nearly flawless function 
through an astounding number of cycles.  The valves face constant blood flow, sharp 
pressure changes, and other environmental stresses that call for an extremely durable and 
specialized structure.  Discussion in this section will primarily concern the aortic heart 
valve.  It is the most commonly diseased and replaced heart valve, with many 
bioprosthetic heart valve replacements being constructed from xenogenic aortic valve 
  4 
tissue [5].  There are some morphological differences between the different heart valves 
of the body, yet their primary compositions are comparable.  For our purposes, 
knowledge of the aortic heart valve will suffice.   
The aortic valve is located at base of the aorta and marks the exit of blood from 
the heart into the body’s vasculature.  The valve leaflets are an extension of the cardiac 
endocardium and fibrous skeleton.  The fibrous ring on which they are positioned is 
known as the aortic annulus [5,6].  This is the main load bearing structure for the valve 
and serves as the transfer point of stresses to the aortic wall [5,11].  Adjacent to each cusp 
are round bulges in the aortic wall that are collectively called the aortic sinuses.  These 
structures prevent valve leaflets from sticking to the aortic wall during opening, and also 
promote the formation of vortices in the blood flow that aid in valve closure [4,7].  Many 
structures contribute to overall aortic valve function, but the cusps will be the main topic 
since they are the primary structures of concern when discussing valve disease and 
replacement [5]. 
Aortic valve cusps are thin and translucent structures composed of connective 
tissue that is roughly semi-circular in shape.  For the most part, they are avascular 
structures.  They primarily support themselves by obtaining nutrients from the 
bloodstream via diffusion [5].  Although the cusps are microscopically complex 
structures, their surfaces contain very few noticeable macroscopic features.  There exists 
a free edge that provides coaptation during closure with up to 40% of cusp surface area 
coming into contact with the other cusps [5].  The cusps are connected to the aortic 
annulus on the opposite side.  This attachment is continuous until terminating at the free 
edge on both ends at the commissures.  Besides these primary points of reference, one 
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side of the cusp is noticeably smoother than the other.  Also, in the center of the cusp 
there is a thick nodular region, the Nodule of Arantius, where all three cusps meet in the 
center during closure [8].  Despite their bland external appearance, the internal 
composition of the aortic valve leaflet is much more interesting.  It is a specialized blend 
of various structures including valvular interstitial cells (VICs), valvular endothelial cells 
(VECs), and large quantities of various extracellular matrix (ECM) components [5,6].   
Figure 2. [A] Aortic valve cusp [4].  [B] Fibrous skeleton and valves of the heart [2]. 
 
1.1.1.1.     Heart Valve Cell Types 
1.1.1.1.1. Endothelial Cells 
Endothelial cells (ECs) are a single layer of cells that are continuous throughout 
the entire cardiovascular system.  This layer of cells lines the lumen of all blood and 
lymph vessels as well as other structures in the bloodstream filling many roles vital to 
normal cardiovascular function [1,2,7,8].  ECs provide the ideal smooth, non-adherent 
A  B 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surface that allows blood components to pass through the valve unimpeded and 
undamaged.  Additionally, through the release of certain biomolecules, ECs also promote 
uninterrupted blood flow through the inhibition of thrombosis and maintenance of 
hemostasis.  Other factors secreted by ECs, as well as certain EC cell surface markers, 
play essential roles in immune and inflammatory responses and contribute to 
management of local blood flow through vasomotion control.  The endothelial cell layer 
also serves as a barrier between the lumen of the blood vessel and the exterior tissues.  It 
not only provides a physical obstruction, preventing the exposure of internal valve 
components, but also controls the passage of nutrients, wastes, cells, and other materials 
by both diffusion and bulk transport into the underlying tissues from the bloodstream 
[1,8].   
 
1.1.1.1.2. Valvular Interstitial Cells 
The other main cell type existing in heart valves is the valvular interstitial cell 
(VIC).  VICs have an elongated cell shape with narrow connecting projections that form 
a network throughout the valvular matrix [26].  These cells, also known as 
myofibroblasts, have the characteristics of both smooth muscle cells (SMCs) and 
fibroblasts and are thought to be primarily responsible for maintaining extracellular 
matrix homeostasis [6,26].  Similar to fibroblasts, VIC metabolic activities are highly 
geared towards producing, degrading, and reorganizing large amounts of matrix 
components [5,6].  However, their SMC-like properties enable them to display contractile 
capabilities which may aid in the maintenance of suitable internal stress levels [26].  The 
distinct contractile and metabolic characteristics of myofibroblasts allow them to 
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uniquely respond to various stimuli.  The specialized nature of VICs enables them to 
respond to the constantly changing body environment and aid in the maintenance of the 
balance necessary for heart valve cusps to perform their intense physiological duties [6]. 
 
1.1.1.2.     Extracellular Matrix 
The majority of connective tissue volume is composed of extracellular matrix 
[1,7].  Heart valve cusps are no exception and are formed from a mixture of collagen, 
elastin and glycosaminoglycans [5,6].  Heart valve durability is strongly based upon the 
condition of the matrix and its ability to remodel efficiently [11].  Each matrix molecule 
has a specific structure and function within the valve, and when arranged accordingly, 
these molecules provide the structural support and flexibility heart valve cusps. 
 
1.1.1.2.1. Collagen 
Collagen is the main structural molecule within heart valve cusp tissue and is also 
the most abundant protein.  Collagen accounts for approximately 90% of heart valve cusp 
protein and about 55% of the young adult human cusp by dry weight [9,10].  There are 
multiple types of collagen present in cusp tissue, with the majority being type I collagen 
(~70%) and the remainder being mostly type III (~25%) [9].  Collagen organizes itself 
into larger fibrous formations, or aggregates, based upon a triple helix molecule subunit 
of three linear amino acid chains wound together.  The resulting long fibrous formations 
enable collagen to exhibit very high tensile strength, but low resistance to torsional and 
flexural stress.  When properly aligned, this organized structure enables collagen to 
provide most of the valve’s matrix strength and durability [13].   
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1.1.1.2.2. Elastin 
Elastin is a branched and coiled protein with the ability to stretch when forces are 
applied [2,7,10].  If the forces are removed, elastin returns to its original state allowing it 
to impart flexibility onto the tissues it inhabits [10,13].  Elastin is rich in non-polar amino 
acids, making it insoluble and giving it a hydrophobic nature [12].  Unlike collagen, 
which can only withstand elongations of 1-2%, elastin can maintain strains of 150% 
without fracture.  However, elastin may improve the elasticity of collagen through 
interfiber connections.  These connections also allow collagen to return to its natural state 
when unloaded, giving aortic valve tissue great strength and extensibility.  Elastin is the 
second most abundant protein in aortic valve cusps and it accounts for 13% of the dry 
weight in young adults [10].   
 1.1.1.2.3. Glycosaminoglycans Glycosaminoglycans (GAGs) are long unbranching polysaccharides composed of  repeating  disaccharide  units  containing  a  hexosamine  and  a  hexuronic  acid,  or hexose  [16].    These  molecules  are  found  in  many  places  throughout  the  body, including cartilage,  tendons, vitreous humor,  synovial  fluid and aortic valve cusps.  There  are  five  main  species  of  GAGs  including  hyaluronic  acid  (HA),  chondroitin sulfate  (CS),  dermatan  sulfate  (DS),  keratan  sulfate,  and  heparin/heparin  sulfate (HS) [17].   Most GAGs are sulfated and can be covalently linked to core proteins in order  to  form  proteoglycans  (PGs)  [18,  19].    However,  non‐sulfated  HA  does  not covalently bind, but instead can act as a core connecting with proteoglycans, such as aggrecan, via link proteins resulting in large brush‐like structures [18‐23]. 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All GAG species have been found in human heart valves, but those primarily found  are  HA,  CS,  and  DS,  with  significant  amounts  in  PGs  versican  and  decorin [18,19,26].   Approximately 60% of  the GAGs  found  in cusp  tissue are HA with  the remainder  being  primarily  CS  (~30%)  or  constituents  of  the  PG  decorin  (~10%) [24, 26].  GAGs are highly anionic due to elevated concentrations of uronic acid and sulfate groups making them very hydrophilic [24].  This allows them to absorb many times their weight  in water and, while only representing 3.5% of cusp dry weight, this  behavior  allows  GAGs  to  substantially  affect  valve  properties,  structure  and biomechanics  [25].    GAGs  play many  roles  in  aortic  valve  structure  and  function. This section includes only a brief overview of GAGs.  For a more detailed discussion please refer to section 1.2.  
Figure  3.  [A]  Large  PG  structure,  aggrecan  bound  to  an  HA  core.  (adapted  from [21]).  [B] Disaccharide unit of the primary aortic valve GAGs (adapted from [17]).   
A 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1.1.1.3.     Aortic Valve Layers 
 Heart valves exhibit three distinct layers that provide various structural and 
functional purposes that contribute to normal valve function.  These three layers, the 
fibrosa, spongiosa, and ventricularis, differ both compositionally and morphologically 
from one another making each specialized in serving its particular purpose.  The fibrosa 
is located on the superior aortic valve surface facing the aorta when the valve is closed. 
The ventricularis is located opposite of the fibrosa and faces the left ventricle while the 
intermediate spongiosa layer forms a barrier separating the other two layers [5,6,14,26]. 
Figure 4. [A] Depiction of aortic valve cusp section showing tri-layered structure 
including basic cell and molecular composition [46]. 
 
1.1.1.3.1. Fibrosa 
The fibrosa faces the exit side of the aortic valve and is the primary load-bearing 
tissue layer [5,6,10,26].  This layer is continuous with the cardiac skeleton and like the 
fibrous ring is composed of high proportions of collagen [6].  The collagen is 
predominantly aligned parallel to the free edge giving it highly aniosotropic properties 
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[5].  Consequently, the aortic valve cusps are extremely yielding in the radial direction, 
yet equally tough in the circumferential.  The higher compliance in the radial direction 
allows valves to open with relative ease in response to blood flow while the strength 
imparted by the circumferentially aligned fibers makes the cusps stand firm when met by 
backflow.  Additionally, the rigidity associated with the aligned fibers keeps the cusps 
taut, which helps promote coaptation and prevents regurgitation [5].   
In order to provide support for the fibrosa’s high radial strains, corrugations are 
present to help mitigate the formation of high stresses [5]. The corrugations of the fibrosa 
facilitate large amounts of cusp expansion and contraction that occur during normal valve 
function [26].  Furthermore, microscopic collagen waves are also present, which makes 
the collagen fibers slightly more extensible and alleviate stresses in the circumferential 
direction [5,10].  Together, the features of the fibrosa make this layer the load-bearing 
workhorse of the aortic valve cusp.   
 
Figure 5. [A] Radial cross-section of porcine aortic valve cusp showing tri-layered 
structure and fibrosa corrugation [5].  [B] Circumferential cross-section of aortic valve.  
View of microscopic collagen crimping [29].   
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1.1.1.3.2. Ventricularis 
The ventricularis is the bottom layer of the aortic valve that faces the left ventricle 
when the valve is closed [5,10,11,27].  This layer is the thinnest layer and is composed 
primarily of dense collagen fibers, which are less orderly than those in the fibrosa [10]. 
The ventricularis is also smoother than the fibrosa and displays a significantly higher 
elastin content through a large proportion of radially aligned elastin fibers [5,11].   The  abundance  of  elastin  fibers is thought to support the maintenance of 
collagen fiber architecture as well as provide elastic recoil during valve function [10].  
This recoil occurs because the ventricularis is naturally preloaded in tension making it 
contract when in the relaxed state [28].  This occurs at the beginning of systole and helps 
snap the valve open quickly.  The preloaded state of the ventricularis also allows the 
valve to exhibit beneficial changes in cusp surface area during opening and closing, 
which helps maximize valve efficiency.  Contraction during opening causes a reduction 
in cusp surface area, which minimizes interference with blood flow while elastic 
stretching during valve closure provides maximum coaptation [5,11].   
Figure 6. Cross-section showing ventricularis and fibrosa changes from systole to 
diastole. (adapted from [4]). 
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1.1.1.3.3. Spongiosa 
The spongiosa is the central layer of the aortic valve cusp that consists of loosely 
arranged collagen fibers and a plentiful quantity of glycosaminoglycan molecules and 
proteoglycans [5,11].  The high GAG and PG content of the spongiosa gives it an 
extremely high hydration capacity.  So, despite its lack of structural strength, the 
spongiosa absorbs large amounts of water and takes on a gel-like structure with 
substantial thickness that demonstrates considerable contribution to overall valve 
function [5,18,29]. 
As mentioned above, the fibrosa and ventricularis undergo a large amount of 
expansion, contraction and bending during normal valve function.  The differences in the 
deformations that occur between these two layers create large amounts of shear stress if 
uninhibited.  The spongiosa acts as a flexible fluid barrier between the two main 
structural layers that minimizes shear stresses by lowering friction.  The lubrication 
properties of the spongiosa allow for great mobility between the fibrosa and ventricularis.  
Alleviation of these high shear stresses that occur during flexure can prevent acute valve 
damage or even separation of the aortic valve layers [5,18,28,29].  
The yielding nature of the spongiosa permits minimal interference with valve 
motion while still providing necessary thickness to the cusp.  Its thickness ensures 
isolation of both the fibrosa and ventricularis and helps prevent tissue buckling [18,31].  
Tissue buckling occurs during bending of the valve at sites of high compressive stress; 
however, GAGs and PGs express a viscoelastic response under compressive loading that 
results in the spongiosa’s high resistance to compressive force and capability of efficient 
shock absorption [5,18,19,30].   
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1.2. Glycosaminoglycans (GAGs) and Proteoglycans (PGs) 
1.2.1. GAG and PG Structure 
As mentioned previously in section 1.1.1.2.3, GAGs are long unbranching 
polysaccharides composed of repeating disaccharide units containing a hexosamine and a 
hexuronic acid or hexose [16].  These molecules are found in many places throughout the 
body including cartilage, tendons, vitreous humor, synovial fluid, and heart valve cusps.  
With the exception of hyaluronan, most GAGs are sulfated and can be covalently linked 
to core proteins in order to form PGs [18, 19].  The presence of these sulfate groups, as 
well as uronic acid residues, makes GAGs and their associated PGs highly anionic.  This 
elevated concentration of charges results in the expression of extreme hydrophilicity [24].   
There are approximately 30 different PG varieties that differ based upon the 
number, size, and type of the attached GAG chains as well as the structure of the protein 
core and location [17].  According to these characteristics PGs are grouped into five 
families.  However, only two significantly associated with aortic valve cusps, hyalectins 
and small leucine rich proteoglycans (SLRPs) [17,19].  Hyalectins are large PGs capable 
of non-covalently associating with hyaluronan via link proteins and include aggrecan, 
versican, brevican, and neurocan [17,22].  Common SLRPs include decorin and biglycan 
which are small PGs consisting of one or two GAG chains attached to a protein core 
containing areas rich in leucine repeats [17,19].   
Chondroitin sulfate (CS) and hyaluronan (HA) represent the large majority of 
GAGs present in aortic valve cusp tissue.  Dermatan sulfate (DS) also has a significant 
presence in smaller amounts and, together with CS and HA, account for 90% of all cusp 
GAGs [19].  These GAGs are primarily found in the form of PGs as versican and decorin 
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[19].  Versican, a large PG, is comprised of 12-15 CS chains that attach to their protein 
core using available serine residues [17].  It is mostly found in the spongiosa layer 
complexed with HA to form large brush-like structures.  Decorin is the most frequently 
found small PG in aortic valve cusp tissue, although biglycan is also found in smaller 
amounts [19,131].  
1.2.2. GAG and PG Function 
The function of PGs is largely controlled by the characteristics of associated GAG 
side chains.  The high concentration of anionic charges on large PG aggregates is a result 
of high CS expression and leads to the absorption and retention of large amounts of water 
[21].  Not only does this play a role in tissue hydration, but also nutrition and solute 
transport as well.  These large, hydrated, brush-like structures take on a gel-like state that 
simulates a porous system limiting the movement of water as well as various solutes and 
nutrients [16].  The micro-flow of water within this networked gel structure, along with 
intra/intermolecular electrostatic repulsions, yields a contribution to the viscoelastic 
nature of cusp tissue [16,17,19,23,130].  These large PG structures have a large 
involvement in valve biomechanics by rendering occupied tissues resistant to 
compression, facilitating efficient load distribution, and enabling reversible deformation 
under mechanical load [16,17,19].  In fact, the osmotic properties of aggrecan have been 
established to provide greater than half of cartilage’s compressive modulus further 
demonstrating the biomechanical importance of these molecules [22].  Additionally, these 
structures can interact with collagen assemblies and have been stated to play a possible 
role in binding specific enzymes or other biosignaling molecules [16]. 
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Small PGs are thought to be associated with the formation and organization of 
other ECM components [17].  Specifically, they interact with collagen through their core 
protein or side GAG chains and play a role in collagen fibrillogenesis [19].  SLRPs 
decorin and biglycan of aortic valve cusps utilize their leucine rich domains to bind to 
fibril-forming collagens.  The full function of these is not known, but they are stated to 
modify the rate of fibril formation as well as play a role in end-stage production or 
termination [21].  Decorin and biglycan have also been suggested to aid in elastogenesis, 
which is supported by the fact that their highest expression is found in the ventricularis 
layer of cusp tissue [131]. 
 
1.3. Native Heart Valve Disease 
Proper heart valve function is necessary to maintain normal blood flow, thereby 
ensuring the transport of vital nutrients throughout the body.  Heart valve disease can 
cause the valves to become dysfunctional, therefore disrupting normal blood flow.  This 
disruption can lead to many symptoms, including shortness of breath, fatigue, edema, 
heart palpitations, chest pain, and even death.  A valve is termed dysfunctional when it 
cannot open properly (stenosis) or close fully (insufficient).  Stenosis causes the valve to 
become a blockage that impedes normal blood flow exiting the heart, while a valve 
insufficiency is best described as a leaky valve that allows back flow or regurgitation 
during diastole.  Stenosis and insufficiency are not mutually exclusive and can occur 
together, although, one usually predominates.  These problems can stem from congenital 
or acquired sources, but regardless of the condition’s origin, diseased valves eventually 
contribute to an increased load on the heart, a common precursor to heart failure [32].   
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Diseased heart valves can often be diagnosed simply by listening to the heart.  
Disruptions in the regular flow produce irregularities in the normal sounds of the heart, 
which can be heard using a stethoscope.  Diseases most commonly affect the aortic and 
mitral valves on the left side of the heart.  Failure of the right side of the heart is usually a 
consequence of left-sided failure and is rarely an isolated incident.  Valve disease, along 
with contributing factors such as heart tissue damage and hypertension, create an 
increased load on the heart forcing the heart to adapt to counteract.  This adaptation 
involves hypertrophy of associated myocytes as well as disruption of the normal structure 
and composition of heart cells and extracellular matrix.  If left untreated, continued 
presence of hypertrophy will commonly lead to heart failure [32]. 
 
 
 
 
 
 
 
 
 
 
 
 Figure 7. Path to cardiac dysfunction [32].  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1.3.1. Congenital Valve Defects 
Congenital heart valve defects exist at birth and are not caused by environmental 
factors, such as diet, lifestyle, or aging.  The most common congenital heart valve defects 
affecting the general population are bicuspid aortic valve and mitral valve prolapse 
(MVP) [11,32,33].  MVP is associated with various inherited disorders; however, the 
underlying disease mechanisms are not well understood and it may also be an acquired 
disease [11].  MVP affects up to 3% of the population and is usually asymptomatic 
leading to discovery during routine examinations [11,32].  Congenitally bicuspid aortic 
valves are similarly common, only affecting 0.5 to 2% of individuals [11,32,33].  In 
addition to defects that directly affect the valves, more systemic disorders can also cause 
valve dysfunction.  These include, but are not limited to, autoimmune diseases and 
connective tissue disorders such as Marfan syndrome.   
Mitral valve prolapse is described as a floppy mitral valve that overextends back 
into the left atrium during ventricular contraction.  This disease is also called 
myxomatous degeneration of the mitral valve, due to the presence of a thickened 
spongiosa resulting from myxomatous material deposition [11,32].  This deposition 
causes the leaflets to become hooded, thick, and rubbery and is accompanied by a 
weakened fibrosa [32].  This disease occurs more often in young women and, though 
mostly asymptomatic, can cause valve insufficiency and lead to serious complications 
[11,32].  However, even asymptomatic mitral valve prolapse has recently been linked to 
serious harmful cardiovascular events including heart failure and death [11]. 
A bicuspid aortic valve is defined as an aortic valve that appears to only have two 
leaflets instead of the normal three.  This abnormality can appear as one normal cusp and 
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a second cusp that is composed of two cusps fused together or, much less commonly, two 
symmetric cusps without signs of fusion.  At early ages, this defect is also commonly 
asymptomatic.  However, bicuspid aortic valve presence predisposes individuals to 
certain complications later in life, such as aortic root dilation, cusp prolapse, accelerated 
valve calcification, and increased susceptibility to infective endocarditis [32,33].   
 
 
 
 
 
 
Figure 8. [A] Depiction of bicuspid aortic valve [33].  [B] Severe hooding and 
calcification in a patient with mitral valve prolapse [32]. 
 
1.3.2. Acquired Valve Diseases 
Acquired diseases are those that are attributed to factors after birth, but can be 
affected by congenital disorders.  Even though these diseases are acquired later in life, 
some congenital disorders can predispose individuals to certain acquired diseases or 
promote the progression of these diseases after they are contracted.  These diseases may 
also be influenced by lifestyle choices, such as diet, activity level, drug use, stress, and 
surgical procedures.  The primary acquired conditions that will be discussed in this 
section are rheumatic heart disease, infective endocarditis, and degenerative diseases.   
A  B 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Rheumatic heart disease (RHD) manifests as valvular defects due to an 
autoimmune response by the body.  Development begins with the contraction of group A 
β-hemolytic streptococci bacteria and, although considered an acquired disease, genetic 
factors also play a role in its development [32,34,35].  Following infection, antibodies are 
produced by the body’s immune system to react with bacterial antigens.  In susceptible 
individuals, these antibodies are also reactive with certain tissue proteins and can target 
the heart, joints, or central nervous system [32,35].  This is called rheumatic fever and 
clinical expression occurs 2-3 weeks after the end of the initial streptococcal infection 
[32].  Only 30-45% of rheumatic fever cases affect the tissues of the heart, while a much 
larger portion (75%) affects the tissues in the joints.  This disease has been largely 
eliminated in industrialized nations.  However, it still remains a large problem in 
developing countries and accounts for close to 250,000 deaths annually worldwide [35]. 
Infective endocarditis (IE) involves the growth of bacterial colonies on the heart 
valves and over 80% of cases are caused by particular strains of streptococci, 
staphylococci, or enterococci.  These particular microorganisms have the necessary 
surface adhesins to overcome the hurdle of attachment to the heart valves and 
surrounding structures.  IE can affect individuals with previously normal healthy valves, 
but valve damage promotes bacterial attachment at the site of injury [36].  Congenital 
valve defects, degenerative valve disease, rheumatic heart disease and mechanical wear 
all cause such valve damage.  Intravenous drug users are also at a very high risk for IE, as 
well as people who recently had catheters or other surgical procedures and patients with 
prosthetic heart valves.  The severity and speed of disease progression varies depending 
on virulence of the organism.  Highly active organisms lead to rapid tissue destruction 
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causing obvious problems of valve insufficiency and heart failure [32,36,56].  More 
benign growths can lead to large vegetations that interfere with normal valve function 
causing leakage or stenosis [56].  In addition, large growths can form infected emboli that 
cause downstream destruction via local tissue necrosis and infection [32,36,56]. 
Degenerative valve diseases are those that occur passively with the wear and tear 
that accompanies age and most commonly include floppy damaged valves, aortic 
dilation, and valve calcification [37].  Individuals who experience congenital and 
acquired diseases that cause valve damage or increase the wear of valve tissues are more 
likely to develop these degenerative diseases and experience faster disease formation and 
progression.  For example, individuals with bicuspid aortic valves develop aortic 
calcification up to two decades earlier than those with normal valves and are more prone 
to aortic dilation [11,32,37-39]. 
The calcification and thickening of the aortic valve is defined as aortic sclerosis 
and is present in over 25% of individuals older than 65 years of age [11,38,39].  Aortic 
sclerosis shares many developmental characteristics with atherosclerosis and is similarly 
influenced by hypercholesterolemia, hypertension, gender, diabetes, smoking, sedentary 
lifestyle and age.  Aortic sclerosis can develop into calcific aortic stenosis, the most 
common cause of aortic stenosis [38-40].  Aortic stenosis is the most prevalent heart 
valve disease affecting 43% of patients with valvular heart disease [41].   
Although valve calcification is still discussed as a degenerative disease, it has 
recently been discovered to also be an active process.  This active process is due to 
macrophage activity and a shift in VIC phenotypes that causes them to express properties 
similar to osteoblasts, which are bone-producing cells [11,38,39,42].  Calcification of 
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valves is of particular interest in research due not only to its prevalence in native valves, 
but also because it is a primary mode of failure in prosthetic valves.   
Together, each year, valvular heart diseases lead to the hospitalization of 93,000 
Americans and are considered the primary cause of death for over 21,000 Americans.  
These diseases are also a major contributing factor in an additional 43,000 American 
deaths annually, not including instances of bacterial endocarditis or rheumatic fever.  
This problem becomes compounded in an aging population as the prevalence of valvular 
diseases is only 0.7% in individuals of ages 18 to 44 as compared to 13.3% in individuals 
75 years or older [41].  Although valvular diseases are responsible for many deaths, 
numerous lives are saved by surgical intervention through heart valve replacement and 
repair.  There are over 290,000 heart valve replacements performed every year worldwide 
with the demand increasing at a rate of 10 – 12% per year [43].  Current heart valve 
replacements are sufficient enough to prolong life in many cases, but they have their 
limitations and cannot yet be considered an equal replacement of the native valve.  
 
1.4. Artificial Heart Valves 
There are four primary types of prosthetic heart valves currently being researched 
that will be discussed in this section: mechanical valves, biological valves, polymeric 
valves and tissue engineered heart valves.  Of these four types, mechanical valves and 
bioprosthetic valves are currently the only ones available for use and each of these has 
their various benefits and drawbacks.  Since a perfect valve replacement has not yet been 
produced, valve type selection is a matter of balancing pros and cons.  When evaluating 
the performance of an artificial heart valve it is important to keep in mind the criteria 
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necessary for an ideal valve substitute.  The list is daunting, but a summary of these 
characteristics is displayed in Table 1, originally stated by Harken in 1962 [44]. 
 
Table 1. Desirable Characteristics of a Heart Valve Substitute [5]. 
Nonobstructive (Not stenotic in any way) 
Quick and complete closure (No valve insufficiency or regurgitation) 
Nonthrombogenic 
Resistant to infection 
Inert in the body (No inflammation or immune response) 
Does not cause blood damage 
Durable for the lifetime of the patient 
Easily and permanently implanted 
Tissue interface with the implant heals properly (No tissue overgrowth) 
Not annoying to the patient (Noise free) 
 
1.4.1. Polymeric Heart Valves 
Polymers possess a wide range of properties that can vary based on molecular 
subunit types, subunit order, presence of cross-linking, molecular weight of 
macromolecules and the type processes used for manufacturing.  We have the ability to 
control all of these things to a certain degree, allowing us to widely control the properties 
of polymeric materials and cater them to our specific needs.  Many polymeric materials 
are well tolerated by the body and are commonly used in the medical industry for a 
variety of applications.  In fact, polymeric materials are present in many cardiovascular 
devices such as catheters, vascular grafts, stents, blood oxygenators as well as current 
artificial heart valves in the sewing rings. 
Polymeric heart valves are a promising topic of research with potential to produce 
valves that combine the best properties of current prosthesis types.  The 
hemocompatibility of many polymeric valves is superior to mechanical heart valves and, 
likewise, there are materials available that are more durable than biological tissues [45].  
However, developing a polymeric material with the proper combination of suitable 
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properties is a difficult task.  Many polymers have been tested in order to find a suitable 
material for heart valve production, but polyurethanes have attracted particular interest 
due to their unique structure [45,46].   
Polyurethanes have a two-phase structure of hard (crystalline) and soft (elastic) 
molecular subunits that gives them a favorable blend of compliance and strength [45,46].  
This allows polyurethanes to closely match the stiffness of natural vessels, which is one 
basis of interest for their use in improved vascular grafts [47].  Polyurethanes also have 
excellent hemocompatibility, but studies using polyurethane in cardiovascular devices 
have suffered from durability problems with both in vivo and in vitro testing [45-47].   
Figure 9. [A] Polyetheretherketone trileaflet valve. [B] Polycarbonate urethane trileaflet 
valve. [C] Polycarbonate urethane bileaflet valve [54]. 
 
Recent research of polyurethane materials has mainly focused on using different 
soft (elastic) segments to improve the long-term durability [45,46].  First generations 
attempted to use polyesters and polyethers; however, these materials degraded due to 
hydrolysis and oxidative damage.  The use of polycarbonates solved some problems of 
these previous generations, but currently experience problems with valve calcification.  
More current polyurethane materials have shown promising results, but no polymeric 
materials are currently approved for prosthetic heart valve use [45,47].   
A  B  C 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Table 2. Summary of polymeric materials in prosthetic heart valve research [45]. 
 
1.4.2. Tissue Engineered Heart Valves 
The basic premise behind this approach involves the use of a degradable three-
dimensional scaffold upon which host cells are intended to grow.  Cells may be intended 
to infiltrate in situ, or tissue regrowth may occur partially or fully in vitro.  The host’s 
cells will eventually completely infiltrate the scaffold as it breaks down leaving behind 
only the living tissue.  Ideally, this type of valve would be functionally identical to the 
healthy native valve resulting in the perfect valve replacement [5,6,11,26,46,54].   
The material requirements for heart valve tissue engineering scaffolds are 
numerous and demanding.  The scaffold itself must be a suitable valve replacement in its 
own right.  It must meet all mechanical and biocompatibility requirements of current 
valve prostheses, with the exception of durability.  This is to ensure that it can support 
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itself until cell infiltration is complete and the resulting tissue can function on its own.  It 
must also support cell growth and degrade at a suitable rate to allow remodeling and 
regeneration [26,46,64].  Most importantly, at no point during the tissue regeneration 
process can mechanical failure occur, or death of the recipient is almost certain. 
 Materials from both natural and synthetic sources have been investigated as 
possible candidates for suitable tissue engineering scaffolds.  The benefit of using natural 
materials is obvious since they offer a more familiar environment for cellular ingrowth 
[11,46].  Collagen, fibrin and small intestinal submucosal matrix along with 
decellularized xenogenic and allogenic valves are among some of the promising 
prospects, but so far none have emerged as a suitable material [46].  Human trials were 
attempted using tissue engineered decellularized porcine heart valves; though, these 
resulted in early failure [11,26,46,65]. 
 This scaffold, SynegraftTM, developed by CryoLife Inc. performed well in animal 
studies using the porcine model.  Structurally whole valve cusps were found in valves 
explanted after 5 months.  These valves showed significant host cell infiltration and 
lacked any signs of valve calcification [26].  Similar implants in the sheep model also 
demonstrated good results in three and six month explants [66].  However, implantations 
of four SynegraftTM valves into children were disastrous.  Three of the children died at 
seven days, six weeks, and one year postoperatively while the last valve was explanted 
after only two days.  The explanted valves showed signs of severe inflammatory response 
and experienced no cell repopulation.  These devastating results call into question the 
reliability of results from current animal models and will have far reaching effects on 
future trials of any tissue engineered heart valves [65].   
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The use of synthetic materials is based around developing biodegradable polymer 
scaffolds.  The ability to control many mechanical properties of these scaffolds as well as 
the degradation characteristics makes this approach particularly appealing.  Polylactic 
acid (PLA), polyglactic acid (PGA), poly-4-hydroxybuturate (P4HB), polycaprolactone 
(PCL), polyurethanes (PUs), and their copolymers are some commonly investigated 
materials for use in synthetic scaffolds [26,54,64,67].  Hoerstrup et al. created scaffolds 
from PGA and P4HB that were seeded and implanted at the pulmonary position in the 
sheep model.  These valves remained functional for 20 weeks and the typical tri-layered 
structure of the native valve was present in explanted valves.  However, these valves also 
showed mild regurgitation and incomplete endothelial cell coverage [26,54,68]. 
The hope of tissue engineering research aims at creating the perfect heart valve 
replacement.  Perfection of this technology could lead to the creation of a working living 
valve with lifelong durability that can remodel, repair, and grow with the patient.  Many 
good results have made us optimistic; however, catastrophic results have also made it 
obvious that many obstacles still remain. 
 
1.4.3. Mechanical Heart Valves 
Mechanical heart valves (MHVs) are those made entirely from synthetic 
materials.  However, for the purposes of this review, this excludes polymeric valves and 
tissue engineering scaffolds.  All mechanical heart valves consist of three major parts: the 
occulder, valve housing, and sewing ring.  The occluder is the only moving part of the 
valve that blocks and opens blood flow.  The housing is the primary structure that 
maintains the integrity of the valve as well as provides vital guidance for the occluder.  
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The sewing ring is a flexible fabric, usually made from ePTFE or Dacron, and is used for 
attachment of the valve to the body.  The main benefit of mechanical heart valves is their 
durability.  Current valves have proven to be extremely long lasting and cases of 
structural failure are extremely rare [48].  However, the nature of MHV materials and 
geometries cause them to express lower hemocompatibility and patients that receive them 
must undergo strict lifelong anticoagulation therapy.   
The level of required anticoagulation therapy is high and given the harshness of 
the required warfarin therapy, elderly patients, patients with bleeding disorders, or 
women who are pregnant or planning on conception should not be recommended for 
MHV replacement.  This makes MHVs the replacement of choice for patients with a long 
life expectancy where anticoagulation therapy is not contraindicated [43,48-51].  
However, even when MHVs are recommended, anticoagulant therapy is still undesirable 
and carries with it the risk of harmful side effects [49].   
 
1.4.3.1.    Background of Valve Types 
The birth of mechanical heart valves occurred in 1952 with the implantation of a 
valve designed by Dr. Charles Hufnagel.  This valve was not implanted at the site of the 
diseased aortic valve, but was instead inserted into the descending thoracic aorta 
[48,50,51].  The Hufnagel valve consisted of a silicone rubber coated nylon ball inside of 
a methacrylate chamber.  This device was not a true valve replacement and was only 
designed to treat aortic valve insufficiency.  The introduction of the Hufnagel valve was 
soon followed by the caged ball valve, which was the first device designed to actually 
replace the native valve [50]. 
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Caged ball valves use a ball as the valve orifice occluder that is retained in a cage.  
After this evolution in design, there have been essentially no mechanical failures 
associated with these valves after over 250,000 implantations [48].  Problems associated 
with the caged ball valves include their bulkiness and risk of thrombus formation.  These 
large valves are centrally occlusive to the bloodstream leading to high transvalvular 
pressure gradients and highly abnormal blood flow.  Switching to the use of a disc 
occluder in caged disc valves proved to be less bulky; however, these also caused high 
central blockage of normal blood flow and experienced high complication rates, which 
sparked the development of tilting disc valves [50].   
Tilting disc valves exhibit marked improvement over previous designs with 
respect to central flow and hemodynamics.  These valves utilize protruding struts to tilt 
the disc during the open phase allowing better central flow [49,50].  The development of 
these valves coincided with the discovery of smooth pyrolytic carbon as an extremely 
tough, thromboresistant material, which quickly became the material of choice for the 
majority of all succeeding mechanical replacements [48,50,51]. 
The current gold standard of mechanical heart valve replacements is the bileaflet 
valve.  When compared to other mechanical heart valves, bileaflet valves display a much 
flatter velocity profile and are heralded as the most hemodynamic valves available today.  
These valves utilize hinges built into the valve housing to guide the rotation of two half 
disc, semi-circle shaped occluders.  This eliminates the need for protruding struts for 
occluder guidance making bileaflet valves the most compact valves offered.  These 
valves have experienced enormous success and currently account for over 80% of 
implanted MHVs [43]. 
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1.4.3.2.     MHV Failure 
1.4.3.2.1. Thrombus Related 
Today’s mechanical heart valves are primarily composed of pyrolytic carbon, and 
although relatively inert in the body, is still a foreign material and can initiate blood 
coagulation through the intrinsic pathway [52].  This problem is compounded in areas 
where stagnant flow is prevalent or where recirculating flow gives time for coagulation to 
occur.  Other flow abnormalities and high-risk areas for hemolysis and platelet activation 
further increase the risk of thrombus formation via the extrinsic pathway [43,49,52].  
High-risk areas include regions where blood experiences high shear stress and places 
where blood damage occurs due to the closing of mechanical structures [43].  Once 
thrombus is formed it can attach and interfere with valve function or embolize and cause 
problems downstream.  The overall incidence rate of these complications is 0.3% -1.3% 
and 0.6% - 2.3% per patient year, respectively [49]. 
 
1.4.3.2.2. Anticoagulant Related 
Patients who receive an MHV replacement are required to undergo warfarin 
therapy to reduce the risk of thrombus related complications.  The level of 
anticoagulation required by a patient is measured using INR, which stands for 
international normalized ratio.  This is a ratio of the patient’s blood clotting time in 
reference to normal clotting time and must be monitored closely [53].  Since 
anticoagulant therapy increases the risk of bleeding complications, attempts are made to 
administer the lowest therapeutic amount.  Still, anticoagulant related hemorrhages occur 
at a rate of approximately 1% per patient year [49]. 
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1.4.3.2.3. Pannus Overgrowth 
Failure from pannus overgrowth occurs when a hyperplasic tissue response causes 
abnormal growth across the sewing ring [54].  Chronic inflammation at the site of the 
implant causes macrophages to merge into multi-nucleated foreign body giant cells in an 
attempt to phagocytose the valve material [55].  This inflammatory response triggers the 
release of various growth factors and cytokines that prompt sustained tissue growth. The 
end result is tissue hyperplasia and a myointimal protrusion that causes narrowing of the 
lumen or prevention of normal valve function [54,55,89].  This occurs mainly on the 
ventricular side of aortic valves and is the primary cause of valve obstruction being much 
more common than thrombus related interference [54].   
Figure 10. [A] Obstructive thrombosis in tilting disc valve. [B] Obstructive pannus 
overgrowth in bileaflet valve. [C] Strut fracture in Björk-Shirley tilting disc valve. [49] 
 
1.4.3.2.4. Infective Endocarditis 
Patients with prosthetic valve implants are predisposed to contraction of infective 
endocarditis, particular in the early post-operation period [36,56].  The incidence rate of 
infective endocarditis is similar in mechanical and bioprosthetic heart valves and is 
associated with a patient mortality rate of approximately 50%, even with surgical and 
medical intervention [32,56].  The disease itself is similar to that of the native valve and a 
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detailed discussion is provided in section 1.3.2.  However, in mechanical valves 
organisms cannot attach to the surfaces of the valve structure itself, which cannot be 
destroyed.  Attachment to the surrounding annulus and sewing ring is still possible, that 
can lead to detrimental tissue destruction and vegetation growth [56]. 
 
1.4.3.2.5. Patient Prosthesis Mismatch 
Rahimtoola first described patient prosthesis mismatch (PPM) in 1978 and this 
phenomenon has been associated with increases in valve replacement mortality rates.  
PPM is used to describe circumstances where a patient has received a valve prosthesis 
that excessively impedes blood flow below the amount required by the patient [54,57].  
High transvalvular pressure gradient is the primary consequence of PPM.  This increases 
the workload of the heart and prevents regression of ventricular hypertrophy. These are, 
as mentioned before, common precursors to heart failure [32,57].  The indexed effective 
orifice area (EOAI), a common predictor of PPM, should ideally be no less than 0.85 to 
0.90 cm2/m2 in order to avoid PPM complications [43,57]. 
       
     
 
 
 
Figure 11. Equation for indexed effective orifice area. 
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1.4.3.2.6. Structural Failure 
Structural failure in mechanical heart valves is extremely rare.  Many models 
have experienced hundreds of thousands of implantations without experiencing a single 
instance of structural malfunction.  However, certain models have been known to produce 
small, but significant, amounts of valves that succumb to some form of structural failure.  
Failure modes have included leaflet fracture, strut fracture, and leaflet escape [48].  
Mechanical failures in MHVs are primarily attributed to three causes [54]:   
• Elevated closing load that exceeds the valve material’s fatigue strength. 
• Material fatigue 
• Cavitation (Phenomenon that causes erosion and pitting via microbubbles [61].) 
Experience from past models has lead to increased knowledge about these failure modes 
sparking necessary material and design improvements.  For this reason, structural failure 
of MHVs has been largely abolished and continued efforts aim to eliminate it completely. 
 
1.4.3.3.     Current Developments 
Current developments in MHVs aim to improve upon flaws in fluid mechanics by 
altering the structural designs.  This will hopefully lead to increased hemocompatibility 
and, in turn, the amount of required anticoagulation therapy.  The ATS Open Pivot® is a 
recent innovative bileaflet valve that claims to possess an improved hinge design.  This 
valve has undergone trials with patients adhering to reduced anticoagulation (INR = 1.5 – 
2.5) with good results [58].  Also, trileaflet valve designs are now emerging that promise 
better central flow, improved hemodynamics, lower impact stresses, lower amounts of 
regurgitation, and reduced risk of cavitation [59,60]. 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1.4.4. Biological Heart Valves 
Biological heart valves are those that are fully or partially composed of biological 
tissues and include those derived from both human and xenogenic sources.  Other than 
mechanical heart valves, bioprosthetic heart valves (BHVs) are the only other 
replacement option currently available.  These valves are hemodynamically superior to 
MHVs due to their anatomical and physiological similarities, and do not require 
anticoagulation therapy.  Even so, the rate of thrombus related complications for BHV 
recipients is similar to that of MHV patients under full anticoagulant therapy [5].  
However, biological valve replacements are far less durable with the majority of valves 
succumbing to structural dysfunction within 12-15 years [62].   
 
1.4.4.1.     Human Tissue Valves 
Human tissue valve replacements consist of allografts (a.k.a. homografts) and 
autografts.  Allografts are typically cryopreserved aortic valves that come from organ 
donors or cadavers [62,69].  The most common cryopreservation technique involves the 
use of 10% dimethyl sulfoxide (DMSO) as a cryoprotectant prior to storage in liquid 
nitrogen.  However, it is debated whether the use of cryoprotectants improves cell 
viability or properly preserves ECM components [63].  Regardless, these valves 
experience extremely good hemodynamics, but suffer from problems with long-term 
durability, as with all biological valve replacements [62,69]. 
The most common form of autograft occurs when the patient’s diseased aortic 
valve is excised and their pulmonary valve is relocated to the aortic position in its place.  
This method is referred to as the Ross procedure and is normally used in children with 
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diseased aortic valves.  This form of replacement gives the child a living aortic valve 
replacement of his or her own tissue with the ability to repair, remodel, and grow with the 
patient.  However, a cryopreserved pulmonary valve allograft is still used in this case, 
which carries with it issues of long-term durability [62,69].  Regardless, this procedure 
may still be beneficial for children considering the drawbacks of pediatric BHV or MHV 
aortic valve replacements. 
Both allograft and autograft procedures allow the patient to have freedom from 
anticoagulation therapy without significant risk of thrombus related events.  However, 
they both also suffer from eventual structural degeneration and lack of long-term 
durability.  These advantages and disadvantages are present for all biological valve 
replacements, though drawbacks of human tissue valves also include low availability 
[62,69].  Allografts and autografts may have their place in certain patients and 
procedures, but with the increasingly large volume of valve replacement procedures 
performed each year, this option cannot be viable as a solution for the general public.  
 
 
 
 
 
 
 
 
Figure 12.  Aortic Homograft after preparation [69]. 
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1.4.4.2.     Xenogenic Tissue Valves 
Currently, there are two primary types of xenogenic tissue that are used in BHV 
fabrication.  These include valves made from whole porcine aortic valves (PAVs) and 
those crafted from cuts of bovine pericardium (BPVs) [5,6,71].  Since xenogenic tissue is 
subject to severe immune rejection, the tissue antigenicity must be removed prior to 
implantation.  Glutaraldehyde treatment sufficiently diminishes tissue antigencity as well 
as crosslinks the tissue, which protects against proteolytic degradation [5,71].  
Glutaraldehyde treatment of these valves is standard, but treatment methods and valve 
designs can vary greatly.  There are many BHV models available today and, although 
widely studied, it is still largely unclear which valves yield the best clinical results.  
 
1.4.4.2.1. Mounting Types 
Valves of each tissue type can be mounted on a stent or manufactured without.  
BHV stents vary by model, but are made from metal or plastic covered in fabric and 
typically have three posts with a sewing ring around the base [5,6,71,72].  Rigid metal 
stents were initially used, however, tears at the commissures in proximity to the posts 
sparked a movement towards the use of flexible stents.  These mostly polymeric stents 
still failed to the same tears, but now also suffered issues from stent creep and 
deformation.  For the most part, this has now been eliminated due better material 
selection and technology, but the benefits of flexible stents are still debatable [71]. 
 Stents are used to make valve handling easier, helping to maintain proper leaflet 
shape and alignment from the time of manufacture.  This stability makes valve function 
more predictable allowing valves to function in the patient as they would in vitro.  
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Surgical implantation of stented valves is also much less technical, as these valves are 
relatively easily attached to the annulus using sutures [71].  Although the use of stents has 
many benefits, the resulting increased profile reduces valve EOA.  This creates 
undesirable transvalvular pressure gradients and has sparked the use of stentless BHVs. 
Figure 13. Various stented BHV valve designs. [A] Hancock IITM (PAV)  [B] 
Carpentier-Edwards (PAV)  [C] Perimount (BPV) [73]. 
 
The benefit of stentless BHVs lies simply in its ability to use a larger valve size 
than a stented valve for any given patient.  This increases the EOA of the valve 
replacement, lowering transvalvular pressure gradients and better supporting ventricular 
mass regression [5,71].  In fact, a short-term follow-up demonstrated 30% lower 
ventricular mass index in patients implanted with stentless valves [74].  However, these 
valves lack the benefits of stented valves and are much more difficult to handle and 
implant.  There is also evidence that these valves will be more prone to failure from 
aortic wall calcification and pannus overgrowth.  This is because increased proximity and 
contact of the xenogenic wall tissue with the host may additionally increase 
immunological and inflammatory responses [5].  The clinical benefit of stentless valves is 
promising but uncertain and only the most highly skilled and experienced surgeons can 
perform implantations [71].  For these reasons, more follow-up studies are needed to 
justify the increased technical difficulties that accompany these valves. 
 A   B   C 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Figure 14. Various stentless BHV valve designs. [A]  Freedom Solo, Sorin Group (BPV) 
[B] Prima Plus, Edwards (PAV) [C] NR200, Shelhigh (PAV) [73]. 
 
1.4.4.2.2. Tissue Types 
The use of porcine aortic valves to construct BHVs is possible due to the high 
amount of similarity between human and pig cardiac anatomy.  In pigs, a muscle shelf 
supports the right coronary cusp and there is a lesser extent of mitral valve to aortic valve 
fibrous continuity, but otherwise, the aortic valves of humans and pigs are very 
comparable [70,72].  Valves made from porcine aortic valves (PAVs) use the aortic valve 
cusps and varying amounts of aortic wall.  The primary structure of PAVs is based on the 
normal anatomy and remains mostly the same between models; however, there are still 
many variations in design as can be seen in the figure above (Figure 15: B and C). 
Stented PAVs differ primarily in stent material and stent design.  The fabric 
coverings and sewing rings are made from Dacron and PTFE with the occasional 
additions, such as silicone inserts.  The stents themselves are made from various metals 
and polymers and most resemble the typical three-post design (Figure 14).   However, 
some valves display vast differences in stent design, such as the BioImplant PAV valve 
that attempted a vast reduction in stent profile (Figure 16).  Some valves also incorporate 
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metals into their sewing rings or stents to render them radioopaque [72].  Most stentless 
PAVs have very minimal additions to the aortic root or any portion of the porcine aortic 
valve, although some of these valves have minimal cloth coverings and diagrams that aid 
in trimming, fitting, and implantation [72,74].  Lower transvalvular pressure gradients, 
better LV mass reduction, and less structural tissue failure has been seen in stentless 
PAVs, but additional follow-up studies are still needed to validate these benefits [74]. 
As mentioned above, there is a muscle shelf supporting the right coronary cusp of 
the porcine aortic valve that is an extension of the ventricular septum [5,70].  This muscle 
tissue inhibits valve motion and is thought to be a promoting site for calcium deposition 
[5,71,72].  Therefore, in an effort to reduce these ill effects, some PAVs remove this 
valve cusp and replace it with an essentially congruent cusp from another valve.  This 
type of PAV is referred to as a composite valve.  Other variations of composite valves 
include tricomposite valves, which use three noncoronary cusps from separate valves.  In 
this design, cusps are matched up for proper geometries to achieve optimal coaptation 
[5,71,72].  These valves have shown fine clinical performance, but more follow-up 
studies are needed to determine the long-term benefits of this approach [71]. 
 
     
 
 
 
 
          Figure 15. Low-profile stent PAV, BioImplant [71]. 
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Like the porcine aortic valve cusp, bovine pericardium is a specialized tissue with 
three distinct layers.  The inner layer that faces the heart is a smooth layer protected by 
visceral mesothelium.  The middle fibrosa layer contains collagen, elastic fibers, 
vasculature, lymphatics, and nerves that comprise the majority of bovine pericardial 
tissue thickness.  Loosely arranged collagen and elastic fibers are abundant in the outer 
layer, which must be cut away from tissue that surrounds the heart.  This trimming leaves 
the outer layer rough, especially when compared to the smooth visceral side.  Pericardial 
BHVs are constructed so that this rough outer layer is positioned facing the inflow.  This 
is to ensure that the rough pericardial surface is thoroughly washed, which helps to 
prevent thrombus related complications [5]. 
Sheets of bovine pericardium permit the production of virtually any needed shape 
allowing for enormous play in BPV design.  Since they are not set in their primary 
structure, like PAVs, BPVs can make modifications as substantial as the number and 
shape of the cusps.  A very popular stented BPV design is a folded cylindrical design 
(Figure 14: C) [71,72].  This design allows stented BPVs to be formed from multiple cuts 
of pericardium or molded from a single section (Figure 17) [6,71].   
BPVs may have slightly better hemodynamics than PAVs due to the completely 
unobstructed flow offered by the cylindrical open position [71].  This may cause them to 
express slightly slower degradation giving them superior durability; however, BPVs often 
suffer from inferior biomechanics, making them prone to commissural tears and single 
leaflet prolapse [71-73].  Despite claims of valve superiority for each type, current overall 
rates of complication for both PAVs and BPVs are similar to that of MHVs, with a 50-
60% rate of death or reoperation after 10 years [5]. 
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Figure 16. [A] Diagram showing construction of a stented BPV [6]. [B] Picture showing 
stented BPV construction from a single pericardium piece [71]. [C] Quadraleaflet 
stentless BPV for mitral replacement, SJM Quattro [72]. 
 
1.4.4.3.     Bioprosthetic Heart Valve Failure 
Failure in BHVs occurs differently between types, but there are general events 
associated with contribution to valve failure that affects all varieties.  These include non-
calcific structural damage and deterioration, calcification, immunological and 
inflammatory responses, paravalvular leaks, pannus overgrowth, infective endocarditis, 
and thrombus related complications.  Structural deterioration and calcification are the 
primary contributors to BHV valve dysfunction, with the majority of BHVs succumbing 
to some form of degenerative disease within 12-15 years [5,62].   
Degenerative modes of BHV failure are highly age and time dependent with lack 
of long-term durability, presenting the biggest drawback for BHVs, especially in younger 
A   B 
C 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patients.  Short-term experience in adults has been excellent with less than 1% of 
implanted PAVs failing within five years.  Failure rates increase to 20-30% at ten years 
and are capped at around 12-15 years, at which point 50% of implanted valves fail.  
These numbers are exacerbated in younger patients where nearly 100% of valves fail 
prior to 5 years in individuals under 35 years old.  When also considering that ten-year 
failure rates fall to 10% in patients over 65, the age-dependence of BHV structural 
degeneration rates becomes obvious [5,62].  Failures from degenerative sources are most 
commonly expressed as valvular insufficiencies from cusp tears, affecting roughly 75% 
of PAVs.  Purely stenotic valves, due to cusp damage or stiffening, occur much less often 
at a rate of approximately 10-15% [5]. 
Non-degenerative events also make contributions to valve failures and are 
important, but thrombus related complications, pannus overgrowth, and infective 
endocarditis are not discussed in this section.  The rate of thrombus related failures in 
BHVs are similar to that of MHVs in patients under full anticoagulant therapy.  This is an 
accepted risk, and when compared to other modes of BHV failure, this problem is minor.  
Infective endocarditis rates are also similar in both BHVs and MHVs at 1-6% and 
although this may still be cause for worry, thorough discussions of infective endocarditis 
are already provided in sections 1.3.2 and 1.4.3.2.4 [56].  Pannus overgrowth was also 
discussed earlier in section 1.4.3.2.3, but section 1.4.4.3.3 provides further discussion.  
All in all, the underlying cause for most modes of valve failure remains the loss of cell 
viability within BHVs.  This disallows normal healing and repair patterns as well as 
removes the ability for the maintenance of cellular and extracellular matrix homeostasis; 
all of which are critical to preservation of normal valve function. 
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1.4.4.3.1. Structural Deterioration (Non-calcific) 
Gradual structural deterioration of BHVs occurs primarily due to changes in 
natural valve biomechanics and loss of cell viability.  These changes cause localized 
stresses in the tissue that can eventually lead to dysfunction in the form of tissue buckling 
or cusp tears [5].  This localized damage may progress slowly, but progresses 
unrestrained since BHVs lack the ability for repair.  Although this form of cusp damage 
is sometimes difficult to discern from calcific effects, since they often occur together, 
non-calcific structural deterioration has been shown to play a major role in BHV failure, 
independent of calcification [81].  In fact, roughly 90% of PAVs fail from some form of 
structural damage with many showing little to no signs of calcification [76]. 
The initiation of tissue deterioration begins before implantation, during tissue 
harvesting and preparation where glutaraldehyde fixation is thought to play a large role.  
Glutaraldehyde causes loss of cell viability and, upon cell death, ECM degrading 
proteases may be released, which cause irreparable damage to the ECM ultrastructure.  
Degradation of collagen fibrils has been observed after fixation, as well as loss of 
collagen associated GAGs and PGs [75].  Increased levels of ECM degrading enzymes 
have also been observed in explanted valves, which further contribute to collagen damage 
and loss of GAGs [82,83].  Glutaraldehyde treatment does not fully prevent enzymatic 
activity and both early and chronic enzymatic presence could have devastating effects on 
ECM integrity [5].  Given the fact that loss of cell viability also eradicates the ability for 
ECM repair, current methods of tissue preparation seem inadequate to sufficiently protect 
the ECM in BHVs. 
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Changes in valve biomechanics also begin with glutaraldehyde fixation.  
Glutaraldehyde effectively removes tissue antigenicity and cross-links collagen to 
support preservation of ECM integrity.  However, formation of collagen cross-links 
paired with lack of ECM remodeling capability results in a locked ECM architecture that 
is unlike its natural dynamic state [84,85].  This results in irregular cusp movement and 
increased cusp rigidity that cause increased stresses, principally at points of high tissue 
flexion [5,77].  In PAVs, this is compounded by the loss of GAGs from BHV cusps, 
which help cusp tissue cope with high compressive stresses.  Glutaraldehyde treated 
BHVs have been shown to lose GAGs both in vitro and in vivo [19,30].  GAGs in the 
spongiosa also provide a shear stress dissipating buffer layer that accommodates motion 
between the ventricularis and fibrosa.  Depleted spongiosa function has detrimental 
effects on BHV biomechanical function and further promotes increased tissue stresses 
and susceptibility to mechanical damage, such as delamination [5,15,18,31,77]. 
 
 
 
 
 
 
 
 
 
      Figure 17. Progressive delamination due to cylic fatigue [77]. 
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1.4.4.3.2. Calcification 
Valve dysfunction due to calcification and related tissue damage is a prevalent 
mode of BHV failure, second only to non-calcific mechanical damage [54].  Calcification 
pathways are not all fully understood, though tissue damage, host responses, and implant 
characteristics are all known contribute to the process.  Calcification occurs in two phases 
initiation/nucleation and propagation of calcific crystals.  Initiation most commonly 
begins below the tissue surface and is referred to as intrinsic calcification [5,78].  
Extrinsic calcification also occurs which can lead to thromboembolic complications, but 
this is much more rare [78].  As calcific crystals propagate and coalesce, tissue 
microstructure begins to deteriorate and stiffness and/or cusp tears may occur [5,75,78].  
Calcification contributes to structural failure over time and affects the long-term 
durability of BHVs.  However, progression of calcification is greatly accelerated in 
younger patients and also contributes to the high short-term failure rate for this group 
[5,78].  Therefore, better understanding of how to prevent this mode of failure could 
greatly expand upon the useful applications of BHVs. 
Formation of calcific nodes in BHVs is thought to be a result of loss of cell 
viability.  Under normal circumstances, low intracellular calcium levels are maintained 
during standard cell metabolic processes.  Upon cell death, this ability is lost allowing 
high concentrations of calcium to saturate remnant cell debris [5,75,78,79].  
Mineralization begins when this influx of calcium reacts with sources of organic 
phosphorus that remain behind, including that from organelles, nucleic acid backbones, 
and cell membranes [78].  Red blood cells and inflammatory cells may also penetrate the 
tissue and accumulate, providing additional nucleation sites for crystal growth [5]. 
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Cellular debris represents the most predominant nucleation site for BHV 
calcification.  Extracellular matrix components are also subject to calcification, although 
modes are less understood [5].  Collagen fibers can serve as nucleation sites for 
calcification, however, only after crosslinking with glutaraldehyde [5,62,75,78,79].  
Elastin calcification also occurs, but does not depend of the presence of crosslinking 
[5,75,78].  This may be a result of the loss of elastin-associated microfibrils, which shield 
elastin from calcification.  These microfibrils are lost during tissue harvesting and 
preparation, possibly due to enzymatic hydrolysis by fibrillin degrading matrix 
metalloproteinases (MMPs).  Conversely, glycosaminoglycans may inhibit calcification 
by chelating calcium to prevent nucleation or sterically through structural interferences 
with hydroxyapatite although this is controversial [75].  However, this has been 
supported by studies in the rat subdermal model where GAG loss was shown to promote 
calcification, whereas GAG fixation showed inhibition [86-88]. 
GAG retention may also reduce calcification through improvements in BHV 
biomechanics.  Regions of increased mechanical stress are known to stimulate 
calcification, and these areas regularly harbor calcium deposits in BHVs.  Maximum 
leaflet flexion occurs at the commissures and basal attachments, and both extrinsic and 
intrinsic calcification is prevalent at these sites of severe tissue deformation [5,62,78].  
Loss of GAGs and glutaraldehyde treatment are thought to increase susceptibility to 
calcification; however, glutaraldehyde fixation is still a necessary standard for BHVs, and 
GAGs are not preserved through this process. 
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Figure 18. Flow of calcification as it progresses from nucleation to BHV failure [78] 
 
 
Figure 19. [A] View of fibrosal side of porcine BHV showing calcification and tears 
after 8 years of implantation in the mitral position [62]. [B] Movat Pentachrome stained 
section of porcine BHV cusp showing calcification (9 years, aortic position) [62]. 
 
A  B 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1.4.4.3.3. Inflammation and Immune Responses 
The contribution of inflammatory and immune responses has been mostly ignored 
as a source of BHV failure.  It has long been known that standard glutaraldehyde fixation 
using low concentrations does not eliminate antigenicity, but merely reduces it 
(approximately by 59%) [5,54,90,91].  Even though antibodies against tissue 
glycoproteins and inflammatory cells have been noted in failed valves, the link between 
these responses and BHV failure has been unclear [5,89].  These subjects have recently 
gained attention as being worth significant research, but the results of various studies 
have been conflicting.  Still, enough evidence has been put forth to warrant further 
investigation into the role of inflammation and immune responses in BHV failure. 
 Remnant immunogenicity after BHV tissue fixation is a result of glutaraldehyde’s 
failure to alter membrane bound receptors or structural glycoproteins [54].  This 
insufficient removal of antigens is thought to result in an increased inflammatory 
response that contributes to decreased durability in BHVs.  Almost monolayer coverage 
by inflammatory cells is found in most explanted BHVs, and it has been proposed that 
this is caused by proinflammatory characteristics of glutaraldehyde itself [89,92].  This 
has been refuted by many studies that demonstrate the use of increased glutaraldehyde 
concentrations to completely suppress immunogenicity will greatly mitigate recruitment 
of inflammatory cells [54,89].  Recruitment of phagocytes is proposed to occur via 
chemoattractants released through opsonization.  This occurs through nonspecific 
mechanisms via the system of circulating complement plasma proteins as well as through 
more specific means that involve the humoral immune response and circulating 
antibodies against BHV tissue glycoproteins [54,55,89]. 
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 There is evidence that these phagocytes contribute to tissue damage leading to 
BHV failure. Studies have shown that intense amounts of phagocytes inhabit valves that 
have experienced failure from tearing [89,93,94].  Also, Dahm et al. demonstrated an 
increased percentage of patients showing BHV component specific antibodies in failed 
valves when compared to patients with functioning valves [95].   Direct observation of 
collagen phagocytosis by macrophages using transmission electron microscopy (TEM) 
was also found in 82% of failed BHVs [96].  To the same end, presence of digested 
collagen was discovered in the cytoplasmic vacuoles of invading macrophages during 
other studies [97].   
 Evidence has also suggested that inflammatory and immune responses play roles 
in other modes of BHV failure as well.  The inflammatory potential of BHV tissue may 
add to the amplification of pannus growth [89].  This is supported by data showing a five 
times reduction in pannus length after six months of implantation in the sheep model with 
BHVs fixed using higher glutaraldehyde concentrations to suppress tissue antigenicity 
and associated inflammatory response [98].  Various groups have also demonstrated links 
to calcification.  Vincentelli et al. showed a 35 times increase in calcification when 
comparing implanted xenogenic tissue to autologous tissue in the sheep model [99].  
Another study provides further evidence of tissue antigenicity’s role in calcification by 
demonstrating that tissue from antigen knockout pigs expressed reduced calcification 
after incubation in human antibodies when compared to normal porcine tissue [100].   
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1.4.4.4.     Current BHV Research 
Since structural damage and calcification are the primary modes of BHV failure, 
most of the current subjects of BHV research concentrate on overcoming these obstacles.  
Main areas of research include: new tissue fixation methods, new BHV materials, and 
anti-calcification treatments.  New fixation methods are currently being researched to 
supplement, alter, or even entirely replace glutaraldehyde fixation.  This approach aims to 
improve the chemistry, micro-architecture, and biomechanics of the BHV ECM in order 
to achieve better long-term preservation.  The search for new BHV materials is similar in 
that improved tissue structure and function is sought to achieve improved long-term 
durability.  In fact, porcine vena cava is currently being researched by a member of our 
lab as a possible alternative to bovine pericardium. 
Large investments of research have been placed on anti-calcification treatments 
due to the relative ease of integration when compared to completely changing material or 
fixation chemistries.  Anti-calcification pretreatments primarily function by targeting the 
first phase of clinical calcification, the nucleation of calcific crystals.  This can be done 
by using inhibitors to interfere with mineral development or through removal of sites 
conducive to crystal formation.  Biphophonates, amino-oleic acid, and trivalent metal 
ions such as aluminum or iron chloride are used to prevent or inhibit calcium phosphate 
crystal formation; while ethanol, decellularization processes, and surfactants are applied 
to remove organic phosphates and other remnant cellular debris that is known to promote 
valve calcification [5,12,78,80]. 
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Percutaneously implanted heart valve research represents a branch of improved 
BHV design.  Instead of focusing on improving the durability of BHVs, the use of these 
valves merely enables us to better cope with current durability problems [54].  
Insufficient durability of a BHVs leads to either failure of the valve or the need for 
reoperation and replacement of the diseased bioprosthesis.  Current replacement surgeries 
are highly invasive and repeat operations are extremely undesirable.  Application of 
catheter based BHV delivery could drastically reduce surgery related patient morbidity 
and mortality rates [102].  This would allow for easier replacement of diseased BHVs as 
well as enable a wider range of the population to be acceptable BHV candidates [101].  
The process involves crimping a BHV down to deliverable size and expanding it at the 
desired site via a balloon expandable or self-expanding nitinol stent.  Although simple in 
concept, all aspects of implantation, including valve compression, delivery, and valve 
function, present problems.  However, new percutaneous valves are being developed and 
this tactic seems to represent the next generation of BHV design [54,101,102]. 
 
 
 
 
 
 
Figure 20. [A] Self-expanding nitinol pericardial BHV by CoreValve [101]. [B] Edwards 
Sapien® balloon expandable BHV [101]. [C] Depiction of catheter and transapical access 
in a BHV leaflet replacement procedure, ValveXchange® [54]. 
C A 
B 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1.5. Heart Valve Biomechanics 
Lack of durability is currently the primary drawback plaguing BHVs.  Barring 
recipient death or malfunction from less prominent sources, failure due to calcification 
and/or structural deterioration is inevitable.  Much of current BHV research has targeted 
reduction of calcification through alternative fixation methods and anti-calcification 
treatments.  If anti-mineralization strategies progress to the point of 100% protection 
against calcification, stability and preservation of the collagenous skeleton would then 
become the limiting factor in BHV durability [122].  Already, 90% of current porcine 
aortic valve BHVs fail due to structural damage, many without signs of significant 
calcification [76,123].  As discussed previously, BHV tissues lack the ability to repair.  
This causes all mechanical damage to be cumulative and leaves prevention as the only 
solution [122].  This damage may also contribute to failure by facilitating proteolytic 
degradation, further suggesting that prevention of this damage may be critical to 
increasing the lifespan of BHVs [123].  The occurrence of this damage is highly 
dependent on cusp mechanics.  Investigation into the biomechanics of both natural and 
fixed valves could provide not only insight into the mechanisms of structural degradation 
but also supply a knowledge base for the development of prevention strategies [124]. 
 
1.5.1. Native Valve Biomechanics 
 Normal aortic valve function is primarily passive, naturally opening and closing 
due to transvalvular pressure changes and direct interaction with the bloodstream.  
However, the term ‘passive’ seems terribly inadequate when describing the complex 
interactions occuring within the specialized tissue layers of aortic valve cusps during 
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normal function.  Internally the tissue is very dynamic, constantly adapting to 
accommodate  the changing mechanical loads [4].  There are three loading modes that 
accompany normal aortic valve function including tension, flexure, and shear.  Tension 
occurs most prominently during valve closure when the valve cusps must expand in order 
to properly coapt.  Shear forces are at their highest when the valve is open and blood is 
rushing parallel to the surface of the ventricularis at high velocities, while flexure occurs 
during the transitions [29]. 
Collagen, which is primarily found in the fibrosa, is the protein that most 
effectively deals with tension.  Proper coaptation is passively facilitated through the 
characteristics and structure of collagen fibers in this layer.  The circumferentially 
aligned collagen fibers provide resistance during full cusp expansion and help maintain 
proper shape.  These taut fibers prevent sagging and prolapse while also aiding in stress 
transfer to the annulus [122].  The low resistance of collagen fibers to torsion and 
bending imparts flexibility in the radial direction, which aids in dealing with rapid radial 
strain changes.  Macroscopic collagen corrugations as well as microscopic collagen crimp 
also lend additional extensibility further enabling cusp expansion and mitigating incurred 
stresses [4].   
The natural curvature of aortic valve cusps is partly maintained by preload present 
in the ventricular and fibrosa.  The fibrosa is naturally loaded in compression while the 
ventricularis is in tension [14,28].  The high elastin expression present in the ventricularis 
utilizes this to provide elastic recoil, which aids in proper opening.  This action also 
minimizes contact with shear forces by reducing the available surface area during the 
open state [5,11].  Flexure occuring during the transition phases causes internal stresses 
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that are attenuated by the spongiosa.  Uneven deformations between the ventricularis and 
fibrosa cause high internal shear stresses to develop at the common boundary.  The 
hydrated GAGs within the spongiosa provide lubrication that alleviates these stresses and 
promotes smoother bending.  Areas of elevated bending that do manifest, harbor high 
amounts of compressive stress.  When left unabated, tissue buckling can occur at these 
points of high stress causing tissue disruption that ultimately contributes to overall valve 
failure [126].  However, the hydrated state of GAGs also allows for absorption of 
compressive loads further providing protection against damage from flexure [15, 31,125].  
 
1.5.2. BHV Biomechanics 
During glutaraldehyde fixation many alterations occur to aortic valve cusp tissue 
that may negatively affect tissue mechanics and, in turn, valve function and durability.  
The formation of crosslinks is essential to the preservation of the collagen structures.  
However, they also lock the microstructure into a static formation, which prevents the 
structural rearrangements that accompany normal function.  The dynamic collagen 
rearrangements occurring during normal function, along with extension of crimp, are 
very responsive to transvalvular pressures.  Rearrangement has been shown to lead to full 
collagen alignment at pressures as low as 4 mmHg, while collagen crimp is largely 
abolished by 20 mmHg [122].  Zero-pressure fixation is thought to minimize the 
consequences of a static ECM by preserving collagen crimp and stress free arrangement.  
While lower pressure fixation has been beneficial, it was demonstrated that the benefits 
of fixation below 4 mmHg is lost early under normal function.  Substantial alignment of 
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collagen was shown to occur during the first 50 million cycles of in vitro, which also 
correlated with decreased tissue extensibility [123]. 
 Increased cusp stiffness also occurs as a result of the crosslinked, static ECM and 
leads to increased compressive stresses during flexure.  Areas of high flexural stresses 
have been demonstrated to generally coincide with increased calcification and have been 
stated by Broom to be the primary culprit of non-calcific tissue damage [124,127].  The 
penalty of these compressive stresses is compounded by the loss of GAGs, which 
diminishes resistance to tissue buckling [31].  Tissue buckling is further promoted by 
increased internal shear stresses resulting from GAG loss, which may also induce 
delamination of the tissue layers.  The end result is the accumulation of damage to 
collagen fibers that eventually leads to BHV failure [15,31,75,77,125].   
 
1.5.3. Characterization of Biomechanics 
Basic characterization of the mechanics of BHV tissue begins with uniaxial 
tensile testing.  When subjected to tensile loads, porcine aortic valve cusps display a non-
linear stress strain curve demonstrating two clearly separate phases of mechanical 
response (Figure 22).  The initial low-stiffness response is dominated by elastin 
contribution and presumably includes elastin stretching, collagen uncrimping, fiber 
rearrangement, and extension of corrugations.  The secondary high-stiffness response is 
dominated by collagen’s input and the higher modulus in this phase is indicative of the 
properties of extended collagen in tension.   
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High-end (collagen) region: 
 
 
   Low-end (elastin) region: 
 
Figure 21. Stress strain curve obtained from uniaxial tensile testing on fresh aortic valve 
cusps in the radial direction. 
Simple tensile testing yields important information on the general extensibility, 
stiffness, and strength of the tissue.  However, it is far from physiologic and cannot be a 
sole indicator of full-scale valve performance.  Biaxial testing overcomes some of the 
downfalls of uniaxial testing and provides a more complete insight into planar tissue 
mechanics [28].  This testing procedure enables coupled analysis of the anisotropic 
behavior of the tissue, but again has its limitations.  Flexural testing allows additional 
insight into tissue mechanics during bending behaviors, providing more information on 
the major deformation mode of aortic valve leaflets [128].  Studying the energy 
dissipation during loading and unloading, or hysteresis, may also be beneficial as it can 
shed light on the viscoelastic characteristics of the tissue [129].  This may be important in 
illustrating the significance of GAG loss and preservation in BHVs as hyaluronan and 
chondroitin sulfate have been demonstrated to affect the viscoelastic properties of the 
ECM and associated fluids [130].  Together these tools can provide us with a very 
comprehensive model for aortic valve cusp tissue mechanics.   
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1.6. Aldehyde Fixation Methods 
1.6.1. Formaldehyde Fixation 
Formaldehyde is a very commonly used biological tissue preservative for many 
lab practices.  It is water soluble up to a saturation point of about 40% and aqueous 
solutions are commonly referred to as formalin.  Prior to the induction of glutaraldehyde 
as the “gold standard” fixative for BHVs, formalin treatments were also considered as 
contenders.  Like glutaraldehyde, formaldehyde crosslinks by reacting with the amine 
groups present on collagen molecules within BHV tissue.  Tissues treated with formalin 
solutions in concentrations from 0.5% to 10% were found to possess the desired tissue 
stability for BHV construction.  However, since formaldehyde is only monofunctional, 
the collagen crosslinks formed are unstable and can be reversed under dynamic 
conditions and during storage.  This phenomenon lead to unsatisfactory long-term 
performance of formalin treated BHVs, heralding glutaraldehyde as a much superior 
BHV fixative.  Still, the low concentrations of glutaraldehyde used for BHV fixation can 
be insufficient to completely sterilize the tissue, leaving formalin treatment to remain in 
use as a post-fixation step for glutaraldehyde fixed BHVs.   
 
Figure 22.  Simplified representation of collagen crosslinking by formaldehyde [103]. 
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1.6.2. Glutaraldehyde Fixation 
Glutaraldehyde is a water soluble, bifunctional aldehyde that is currently the 
industry standard fixative for bioprosthetic heart valve tissue.  Glutaraldehyde renders 
BHV tissue resistant to autolytic degradation by the creation of Schiff-base crosslinks 
between primary amines present on lysine and hydroxylysine of collagen molecules 
[5,103].  Glutaraldehyde is also able to polymerize through aldol condensation, allowing 
the formation of crosslinks of variable length [103].  In addition, partial sterilization and 
immunogencity masking is accomplished through glutaraldehyde treatment, which is 
necessary to prevent infection and immune rejection [5,6,54,71].  Various glutaraldehyde 
treatments have been used since the 1960s and continue to demonstrate their 
effectiveness, with the majority of adult implanted glutaraldehyde fixed BHVs currently 
lasting 12-15 years before failure [62,103].  However, glutaraldehyde fixation has been 
linked to various modes of BHV failure and this process has repeatedly been under fire as 
an area for improvement or replacement. 
Glutaraldehyde is widely known to compromise the normal tissue mechanics of 
the aortic valve.  However, various pressure fixation techniques have been developed to 
help reduce this phenomenon.  First generation porcine BHVs were fixed under a 
backpressure of 80 mmHg, similar to natural diastole.  This fixed the valve in the closed 
position, which yielded a visually pleasing, smooth cusp shape and proper coaptation.  
However, high-pressure fixed BHVs were soon found to have inferior biomechanics and 
durability due to excessively rigid cusps.  The high-pressure fixation technique was found 
to extend macroscopic collagen corrugations as well as microscopic crimp, therefore 
locking collagen fibers into an elongated position and greatly reducing cusp flexibility.  
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Following generations have employed low-pressure and zero-pressure fixation techniques 
that possess improved tissue biomechanics and overall long-term durability [71]. 
  Despite fixation process improvements, collagen microarchitecture still becomes 
locked into its initial fixed configuration, preventing the dynamic ECM restructuring that 
accompanies normal valve function.  This results in stiffer, less compliant tissue that is 
more prone to tissue buckling and other localized mechanical stresses [5].  Tissue 
mechanics are further skewed by the loss of elastin and GAGs, other important cusp 
components that contribute to normal function.  These molecules do not possess the 
amine functionalities necessary for crosslinking by glutaraldehyde and are lost during 
preparation, storage, and function.  GAG loss stems primarily from the spongiosa layer, 
which normally functions to reduce internal shear stresses, absorb compressive stresses, 
and prevent tissue buckling [15,18,19,25,31,75].  The loss of these important functional 
molecules and the resulting changes in tissue mechanics may contribute to structural 
deterioration, the foremost cause of BHV failure. 
Glutaraldehyde fixation has also been linked with calcification, the other major 
means of BHV failure, as was previously discussed in section 1.4.4.3.2.  Although 
mechanical damage has a well-known synergy with calcification, glutaraldehyde fixation 
has also been directly linked to calcification through various other pathways [5,62,78].  
Devitalization and other cell alterations result in the formation of cell debris, which 
function as nucleation sites for mineralization [5,6].  Glutaraldehyde is thought to 
stabilize these structures, although some studies using high concentrations of 
glutaraldehyde has shown shielding effects against calcification [78].  Residual unreacted 
glutaraldehyde has also been implicated in calcification and the use of amine 
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neutralization treatments have shown to nullify mineralization [6].  Many other anti-
calcification strategies have been researched and were lightly discussed in section 1.4.4.4.  
However, a more in depth look at one approach, alternative fixation methods, is provided 
in section 1.8.   
Figure 23. [A] Free glutaraldehyde molecule and its polymeric form after aqueous 
uptake [B] Simplified example of crosslinking between two collagen molecules using 
glutaraldehyde (Both figures adapted from [103]). 
 
1.7. Alternative Fixation Methods 
The perceived contributions of glutaraldehyde treatment to BHV failure have lead 
to a search for suitable alternatives.  Alterations to glutaraldehyde fixation methods as 
well as replacements have been pursued in recent years.  Modifications have ranged from 
changes as simple as using higher concentrations to more involved strategies that reduce 
tissue reactivity, block residual aldehyde groups, or incorporate into the crosslinks 
[78,104].  Some non-glutaraldehyde tissue fixatives that have been investigated include: 
epoxy compounds, such as triglycidalamine [105]; carbodiimides [103,114-120]; 
acylazides [103]; poly-glycidyl ethers [106]; reuterin [107]; genipin [108]; glycerol 
[103]; sodium metaperiodate [88]; diisocyanates [103]; and dye-mediated photooxidation 
A  B 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[109-112].  Many of these fixatives have yielded promising results through preliminary 
testing, but there has been minimal conversion into clinical use.   
The primary focus of many studies involving these new chemistries has been on 
the reduction of calcification, though there are additional benefits that may also 
accompany the nature of this strategy.  Possible benefits include: potential enhancement 
to tissue stability, improved biomechanics, and reduction of fixative toxicity.  However, 
the use of entirely new fixation chemistries also risks providing inadequate tissue 
durability as well as stimulating unknown host responses.  BHVs crosslinked by dye-
mediated photooxidation and carbodiimides have progressed to clinical trials; however, 
neither has yet further advanced to regular clinical use.  Both of these particularly 
promising compounds do not become incorporated into the tissue, but merely catalyze the 
formation of covalent bonds within the tissue.  This particular characteristic all but 
ensures reduced toxicity and early results have demonstrated reduced calcification in 
tissues crosslinked by each treatment [109-111,116-119].  The use of these new 
crosslinking methods, along with proper valve construction, may improve the average 
lifetime of BHVs representing the next evolution in their design. 
 
1.7.1. Dye-mediated photooxidation 
Fixation processes using dye-mediated photooxidation are fairly simple and 
include incubation in the photooxidative dye of interest, followed by exposure to specific 
wavelengths of light in an aerobic environment.  However, the mechanisms behind this 
method of crosslink formation are not fully understood [111-112].  After light absorption 
by the dye, excitation initiates the crosslinking response that is theorized to include 
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reactions involving singlet oxygen and amino acids with the light-excited dye [112].  
Methylene blue and methylene green are two dyes that have been investigated for use in 
BHV fixation [109-112].  Investigation of multiple dyes has also been augmented by 
exploration of differing wavelengths of light as well as varying lengths of exposure [112].   
In addition to demonstrating resistance to enzymatic degradation and 
calcification, tissues crosslinked using dye-mediated photooxidation have also exhibited 
low immunogenicity, non-cytotoxicity and seemingly improved physical properties [109-
112].  One particular fixation method, PhotoFix®, progressed to clinical trials but was cut 
short due to excessive regurgitation prior to two years.  However, upon explantation, 
valves consistently exhibited signs of failure due to improper design while tissue 
performance seemed to be satisfactory [113].  Nonetheless, this has been a setback for the 
advancement of PhotoFix® and other alternative fixation chemistries; as the previously 
mentioned study suggests, current testing methods may be inadequate to properly predict 
clinical performance. 
 
1.7.2. Carbodiimide Fixation 
Water-soluble carbodiimides have also attracted a great deal of interest for use in 
alternative fixation methods.  A popular pair of carbodiimide crosslinkers that have been 
investigated for use in BHV tissue fixation are 1-ethyl-3-(3-dimethylaminopropyl) 
carbodiimide (EDC) and N-hydroxysuccinimide (NHS).  As mentioned previously, these 
reagents react to produce zero-length bonds within the tissue.  This refers to the fact that 
neither EDC nor NHS remains in the bond after crosslink formation, but merely catalyzes 
the formation by utilizing available amino acid side groups [103,114-120].   
  63 
Collagen crosslinking is initiated when EDC activates carboxyl groups on aspartic 
and glutamic acid, which then reacts with NHS to form a stable intermediate.  NHS 
allows for increased crosslinking yield and facilitates reaction with nucleophiles, such as 
primary amines on lysine and hydroxylysine of collagen [114,115].  There is also 
evidence that these activated carboxyl groups can form ester crosslinks with hydroxyl 
groups, furthermore, in sufficient quantity to significantly affect tissue mechanics [114]. 
  Tissue mechanics is a concern with carbodiimide crosslinked tissue as the zero-
length bonds produced by crosslinks have been stated to yield undesirable collagen 
stiffness [116].  As such, some groups have investigated the incorporation of diamine 
spacer molecules into carbodiimide crosslinks that create “lengthened” bonds.  These 
strategies aim to both enhance tissue stability and reduce stiffness, although, the majority 
of these alternative fixation studies have primarily focused on the reduction of 
calcification [116-119]. 
The amide bonds formed by EDC/NHS fixation are more stable than the Schiff-
base bonds created by glutaraldehyde fixation, and it is theorized that carbodiimide 
crosslinking may offer superior collagen stability [117].  This theory is also suggested 
through a hypothesis submitted by Weadock et al., which proposes that improved 
stability is afforded due to the formation of a larger number of crosslinks using 
EDC/NHS treatment [115,121].  In addition to the collagen stability afforded by 
EDC/NHS fixation, GAGs can also be crosslinked through carbodiimide chemistry due to 
the high amount of available carboxyl groups situated on GAG molecules (Figure 3).  
The preservation of GAGs may further protect collagen sterically through the blockage of 
cleavage sites that are vulnerable to enzymatic attack [115].  GAGs may also improve 
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tissue stability through the improvement of tissue and valve biomechanics.  Even slight 
improvements could delay the onset of fatigue damage and, as a result, slow structural 
degradation.  Also, since EDC/NHS crosslinked tissues have exhibited resistance to 
calcification, carbodiimide crosslinking becomes an even more attractive alternative to 
glutaraldehyde fixation for improved BHV durability [116-119].   
Figure 24.  Representation of carbodiimide crosslinking in the presence of NHS [120]. 
 
1.8. GAG Loss in BHVs 
Glutaraldehyde is currently the standard treatment used for the preservation of 
tissue structure.  Although it is effective at collagen stabilization, it fails to preserve both 
GAGs and elastin because they lack the amine functionalities necessary to be crosslinked.  
The loss of GAGs has been demonstrated to occur during preparation, storage, cyclic 
fatigue, and implantation [15,18,19,30,75].  The effects of this GAG loss on the ultimate 
failure of BHVs is unclear, but has been theorized to contribute to both major modes of 
malfunction, including calcification and structural damage. 
Versican and HA aggregates have been demonstrated as the primary contributors 
to overall GAG loss.  This is most likely due to steric hindrance from side GAG chains 
preventing the crosslinking of protein cores within these aggregates.  Also, these 
molecules are for the most part unbound, especially in the spongiosa, leading to loss by 
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leaching.  This is opposite smaller PGs, like decorin, which are better preserved.  The 
protein cores of smaller PGs are less obstructed by GAG chains and are therefore more 
open to crosslinking [19].  However, given the function of these small PGs, it is unlikely 
that they would have any beneficial effect on the lifeless tissues of BHVs [17,19, 21]. 
 The role of GAG loss in structural damage is thought to be particularly 
significant and starts with detrimental changes to tissue biomechanics.  This primarily 
concerns the loss of GAGs associated with the PG versican within the spongiosa.  The 
loss of the primary component of this important tissue layer increases internal shear 
stresses and has been shown to cause increased flexural rigidity [18].  The increased 
flexural stiffness also brings about increased compressive stresses during flexure, and 
GAG depleted tissues have been shown to be more prone to tissue buckling [31].  
Versican expression has been demonstrated to be highest in the spongiosa, and losses of 
versican and HA aggregates have been shown to be the primary contributors to overall 
GAG loss [19,131].  This further supports the fact that versican aggregate loss from the 
spongiosa is the primary contributor to the deterioration of valve biomechanics. 
The loss of GAGs may also contribute to calcification, although indirectly, as 
areas of high flexural stresses have also been demonstrated to generally coincide with 
increased calcification [124,127].  More direct relationships are also possible as versican 
is associated closely with elastin networks and versican expression has been verified to 
be second highest in the ventricularis [19,131].  Unlike collagen, purified elastin has been 
shown to calcify heavily, regardless of crosslinking; while versican binding, under 
normal conditions, has been implicated as an inhibitor to elastin calcification [19].  GAGs 
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may also prevent hydroxyapatite nucleation through the chelating of calcium, which 
inhibits reaction with extracelluar phosphate [75]. 
 
1.9. GAG Preservation Strategies 
As mentioned in the previous section, it has been demonstrated that GAGs are lost 
from BHV tissues during preparation, fatigue, implantation, and storage [15,18,19,30,75].  
GAGs are thought to be vital to the proper biomechanical function, and discussion of 
their structure and function has been laid out in sections 1.1.1.2.3, 1.1.1.3.3, 1.2, 1.5, and 
1.8.  They reside primarily within the central spongiosa layer of cusp tissue and their loss 
has been attributed to increases in tissue buckling depth as well as flexural rigidity 
[18,31].  These changes may cause additional undue stresses on BHV tissue, which 
damage collagen fibers and ultimately lead to BHV failure. 
Our lab has attempted to improve GAG preservation using various crosslinking 
strategies.  Sodium metaperiodate and carbodiimide crosslinking using EDC/NHS have 
exhibited improved GAG stabilization when coupled with glutaraldehyde fixation 
[30,31,88,132,133].  Sodium periodate has been evaluated without the addition of 
glutaraldehyde, but was found to provide insufficient collagen stability [88].  Regardless, 
it has been shown that none of these fixation chemistries were adequate to fully preserve 
GAGs when subject to enzymatic degradation [30,88,132,133].  Therefore, it was 
hypothesized that a GAG degrading enzyme inhibitor needs to be employed in order to 
provide full protection against GAG loss. 
Neomycin trisulfate, a hyaluronidase inhibitor, has an ideal structure for this 
function and possesses multiple amine functionalities that allow it to be incorporated into 
  67 
BHV tissue by using numerous crosslinking strategies.  Neomycin prevents the 
enzymatic digestion of GAGs both by the blocking of active cleavage sites as well as 
through binding and interacting with hyaluronidase.  The presence of hydrophilic groups 
in combination with lipophilic residues facilitates this binding and allows neomycin to 
sterically interfere with the active site of hyaluronidase, subsequently causing a 
conformational change that renders the enzyme ineffective [31,133].   
 Neomycin has been demonstrated to supplement GAG protection in cusp tissue 
when subjected to both cyclic mechanical fatigue and storage.  This was demonstrated in 
tissues crosslinked with both EDC/NHS and glutaraldehyde as well as in tissue fixed 
using glutaraldehyde alone [30,UD*].  Reduced tissue buckling was found in these 
tissues, providing further evidence of the importance of GAG preservation [31].  In 
addition to improved GAG stability, collagen and elastin were also further stabilized by 
neomycin through unidentified mechanisms [30,UD].  Altogether, the incorporation of 
neomycin into BHV tissues helps prevent GAG loss, which may contribute to better 
overall ECM stability. This may increase BHV durability by delaying the mechanisms 
that lead to structural damage and ultimately BHV failure.  (*UD=unpublished data) 
 
 
 
 
 
 
Figure 25. Structure of neomycin trisulfate (www.sigmaaldrich.com). 
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2. RESEARCH RATIONALE 
2.1. Overview 
Lack of long-term durability remains the primary concern for BHVs with the 
majority failing within 12-15 years after implantation into adults.  Although this may be 
adequate for many patients, BHV implantation can be contraindicated in younger 
individuals in order to avoid reoperation.  Even in elder recipients, valve dysfunction can 
still cause death or reoperation that could be avoided with increased BHV durability.  
Therefore, investigation into methods for increased BHV durability is warranted in order 
to both widen the patient demographic as well as improve the quality of life for BHV 
recipients. 
Improving BHV durability requires prevention of the two foremost causes of 
failure, calcification and non-calcific structural degradation.  Glutaraldehyde crosslinking 
has been implicated as a contributor to both of these phenomena and has long been a 
target of improvement or replacement.  Investigation into alternative fixation methods has 
yielded many options, many of which have demonstrated increased resistance to 
calcification.  However, even with a fixation method that offers 100% reduction of 
mineralization, structural damage from mechanical sources would still lead to failure.  
This requires the development of fixation strategies that not only reduce calcification, but 
also resist the accumulation of structural damage. 
The accumulation of non-calcific damage is highly dependent on cusp mechanics, 
and even minor biomechanical alterations can have profound implications on the fatigue 
life of BHVs.  This stems from the lack of tissue repair mechanisms that leads to a 
cumulative effect for all incurred mechanical damage.  Important biomechanical 
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molecules, GAGs, are not crosslinked by glutaraldehyde fixation and are consequently 
lost during implantation, storage, and cyclic mechanical fatigue.  The increased flexural 
rigidity and tissue buckling that results from GAG loss may have direct repercussions on 
collagen integrity, which leads to cusp tears that cause valve insufficiency and failure. 
Carbodiimide crosslinking using EDC and NHS is a particularly promising 
alternative fixation treatment.  This method of crosslinking is capable of reacting with 
carboxyl groups as well as amines, enabling the crosslinking of both GAGs and collagen.  
This difference in crosslinking chemistry also causes changes to the ECM 
microarchitecture that may affect mechanical properties.  As a result, improvements to 
tissue mechanics may occur through increased GAG preservation along with differing 
crosslink architecture.  Additionally, tissues crosslinked using EDC and NHS have 
demonstrated improved resistance to calcification using in vivo models. 
The crosslinking of GAGs alone may not be sufficient to preserve them, since 
they are still be prone to loss through enzymatic degradation.  The use of neomycin, a 
hyaluronidase inhibitor, additionally protects GAGs by preventing enzymatic cleavage.  
Integration of neomycin into tissues is facilitated by the presence of multiple amine 
groups that permit integration into carbodiimide-initiated crosslinks. 
We propose that the addition of neomycin into EDC/NHS fixation will 
demonstrate superior GAG stability while also exhibiting reduced calcification when 
compared to glutaraldehyde crosslinked tissue.  Cusp tissue will be treated as such and 
assessed for general tissue stability as well as for the ability to resist GAG loss from all 
sources.  Basic mechanical testing will also follow in order to obtain initial 
characterization on the effects of this crosslinking method on tissue mechanics. 
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2.2. Specific Research Aims 
2.2.1. Aim I: What is the optimal concentration of neomycin needed to improve 
GAG preservation during in vitro degradation and storage? 
 
Hypothesis:  GAGs may be stabilized through EDC crosslinking due to bonding of 
available carboxyl groups to free amine groups on collagen.  The presence of bound 
neomycin may further stabilize GAGs through the prevention of enzymatic degradation. 
Experimental Plan:  Porcine aortic valve cusps will be treated using various 
concentrations of neomycin and then subjected to enzymatic degradation.  Tissues 
crosslinked using the optimal treatment will be compared to EDC treated tissue with an 
inert amine functional molecule added in order to verify the specific contribution of 
neomycin to GAG preservation.  GAG stability will be measured after enzymatic 
degradation and storage.  Tissue GAG content will be quantified using hexosamine and 
DMMB assays, in addition to being visually verified via histology. 
 
2.2.2. Aim II: Does neomycin further enhance EDC crosslinking of collagen and 
elastin in porcine aortic valve cusp tissue? 
 
Hypothesis:  The available amine functionalities on neomycin may enable interaction 
with EDC/NHS during crosslinking.  The incorporation of neomycin into crosslinks may 
affect the stability of collagen and elastin. 
Experimental Plan:  NEN treated porcine aortic valve cusps will undergo collagenase and 
elastase treatment.  Resistance to enzymatic degradation will be used as an indicator of 
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elastin and collagen stability.  Differential scanning calorimetry will also be used to 
detect any changes in the collagen denaturation temperature of the tissue.  Data will be 
compared to that of a GLUT control as an indicator for baseline performance. 
 
2.2.3. Aim III: Does neomycin used with EDC crosslinking demonstrate improved 
in vivo performance? 
 
Hypothesis:  The physical crosslinking along with neomycin protection in the NEN 
treatment may prevent the loss of GAGs due to in vivo degradation.  Calcification may 
also be reduced for the NEN group due to the lack of glutaraldehyde crosslinks. 
Experimental Plan:  Rat subdermal implantation will be used to assess the performance of 
various crosslinking strategies.  Hexosamine assay will be used to quantify the remaining 
GAGs after implantation, while atomic absorption spectroscopy will be used to quantify 
mineralization.  Results will be also verified visually via histology. 
 
2.2.4. Aim IV: Does neomycin used with EDC crosslinking affect the stiffness and 
extensibility of porcine aortic valve cusp tissue? 
 
Hypothesis:  The unique crosslinks formed within the NEN treated groups may cause the 
cusp tissue to exhibit different levels of stiffness and extensibility when compared to 
fresh tissue and GLUT fixed tissue. 
Experimental Plan:  Uniaxial tensile testing will be used to analyze stress-strain 
relationships for all groups in both the radial and circumferential directions.   
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3. MATERIALS AND METHODS 
3.1. Materials 
Ammonium acetate, calcium chloride, chondroitinase ABC from Proteus vulgaris, 
collagenase type VII from Clostridium histolyticum, 1,9–dimethylmethylene blue 
(DMMB), (D+) glucosamine HCl, hyaluronidase type IV-S from bovine testes, 
chondroitin sulfate C sodium salt, and neomycin trisulfate hydrate were all purchased 
from Sigma-Aldrich Corp (St. Louis, MO).  Acetyl acetone, TRIS buffer, glycine, 
hydrochloric acid, sodium azide, p-dimethylaminobenzaldehyde, and 4-(2-hydroxyethyl)-
1-piperazineethanesulfonic acid (HEPES) were purchase from Fisher Scientific (Fair 
Lawn, NJ).  Sodium Chloride, sodium carbonate, and 1,6-hexane diamine was purchased 
from Acros Organics (Morris Plains, NJ).  Elastase from porcine pancreas (135 U/mg) 
was purchased from Elastin Products Company (Owensville, MO).  EM Grade 
Glutaraldehyde- 8% wt. in H2O was purchased from Polysciences Inc. (Warrington,  PA).  
2-(N-morpholino) ethanesulfonic acid (MES) and Ultra II ultra pure hydrochloric acid 
was purchased from J.T Baker (Phillipsburg, NJ).  n-hydroxysulfosuccinimide (NHS) 
was obtained from Pierce Biotech (Rockford, IL).  Lanthanum(III) oxide was purchased 
from Alfa Aesar (Ward Hill, MA).  10% buffered formalin, 1-ethyl-3-(3-
dimethylaminopropyl) carbodiimide (EDC), and isopropyl alcohol were purchased from 
VWR International (West Chester, PA).  Sodium Phosphate (dibasic) was purchased 
from EMD Chemicals (Gibbstown, NJ).  Porcine aortic valves from Snow Creek Meat 
Processing (Seneca, SC). 
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3.2. Methods 
3.2.1. Porcine Aortic Valve Acquirement 
Fresh porcine aortic valves were harvested on site at a local slaughterhouse, Snow 
Creek Meat Processing (Seneca, SC).  Valves were excised immediately upon animal 
death and were removed by cutting just below the aortic cusps and just above the aortic 
sinuses.  The valves were transported on ice back to the laboratory where the valves were 
rinsed thoroughly using physiological saline.  The valve leaflets were then separated and 
excess muscle tissue, aortic wall, and fat was removed leaving only the leaflet tissue and 
approximately 0.5 cm to 1 cm of aortic wall connected beyond leaflet to wall interface.  
After rinsing and trimming, all tissue was subject to immediate fixation. 
 
3.2.2. Tissue Fixation Methods 
For all fixation steps, 33 mL of fluid was used per valve cusp.  Fixation processes 
were carried out at room temperature within 4 hours of harvesting and were as follows: 
 
CONTROL GROUPS: 
GLUT: Tissue was placed in 0.6% glutaraldehyde in 50 mM HEPES buffered saline (pH 
7.4) for 24 hours.  Solution was then replaced with 0.2% glutaraldehyde in 50 mM 
HEPES buffered saline (pH 7.4) for another 6 days.   
 
EDC: Tissue was placed in 30 mM 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) and 6 mM N-hydroxysuccinimide (NHS) in 50 mM MES buffered saline (pH 5.5) 
for 24 hours.  Valves were then placed in 10% formalin (pH 7.4) for another 6 days.  
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EXPERIMENTAL GROUPS: 
NEN: Tissue was placed in 0.5 mM neomycin trisulfate in 50 mM MES buffered saline 
(pH 7.4) under constant orbital shaking for 1 hour.  After incubation in neomycin, 
fixation proceeded identical to the EDC fixation method.   
 
NOTE: 
• NEN refers to valves that underwent fixation as above.  If a concentration is 
specified, this refers to a change in neomycin trisulfate concentration only.  If left 
unspecified, 0.5 mM neomycin trisulfate concentration should be assumed.   
 
EXPERIMENT SPECIFIC CONTROL GROUPS: 
HEX: Tissue was placed in a 1.5 mM solution of 1,6-hexanediamine in 50 mM MES 
buffered saline (pH 5.5) under constant orbital shaking for 1 hour.  Fixation then 
proceeded identical to the EDC fixation method.  ***HEX was used to provide a control 
for neomycin’s amine functionalities and their contribution to ECM preservation.*** 
 
NEX: Tissue was placed in 0.5 mM neomycin trisulfate in 50 mM MES buffered saline 
(pH 7.4) under constant orbital shaking for 1 hour.  After incubation in neomycin, tissue 
was placed in 30 mM (EDC) and 6 mM (NHS) in 50 mM MES buffered saline (pH 5.5) 
for 24 hours.  Tissue was then stored in a solution of 80% 50 mM HEPES buffered saline 
(pH 7.4) and 20% isopropyl alcohol.  ***NEX was used to provide a control for 
formaldehyde and its contribution to collagen stability.*** 
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NOTES: 
• Valves not used immediately were stored in their final fixation solution until needed. 
• After fixation, immediately prior to all experiments, aortic wall tissue was separated 
from leaflet tissue and discarded. 
 
3.2.3. Enzymatic Degradation of GAGs 
GAG degrading enzyme solution (GAGase): 5 U/mL hyaluronidase and 0.1 U/mL 
chondroitinase in 100 mM ammonium acetate buffer (AAB, pH 7.0).  Leaflets were 
thoroughly washed in 100 mM AAB for 3 changes of 5 minutes each.  Leaflets were then 
approximately cut into two equal halves and briefly blotted dry.  Half of each cusp was 
put into 1.2 mL of GAGase, while the other half was put into 1.2 mL of AAB as a 
control.  Both groups were incubated under high agitation at 37°C for 24 hours.  After 
incubation, leaflets were removed from solution and thoroughly rinsed in distilled water.  
All solutions were saved for both DMMB and hexosamine analysis, while the tissue was 
blotted dry, frozen, and saved for hexosamine analysis (Sections 3.2.4 and 3.2.5). (n=6) 
 
3.2.4. GAG Quantification: Hexosamine Assay 
Tissues were lyophilized, weighed, and then acid hydrolyzed in 2 mL of 6 M HCl 
for 20 hours at 95ºC.  Resulting solutions were then dried under nitrogen gas and re-
suspended in 2 mL of 1 M NaCl.  These were reacted with 2 mL of 3% acetylacetone in 
1.25 M sodium carbonate solution for 1 hour at 95°C and let cool to room temperature.  
The following were then added to each sample followed by vortex mixing: 4 mL of 100% 
ethanol and 2 mL of Ehrlich’s reagent (.18 M p-diemethyl-aminobenzaldehyde, 50% 
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ethanol in 3.0 N HCl). Samples were allowed to sit at room temperature for 45 minutes to 
allow sufficient reaction time.  The resulting color product indicative of hexosamine 
quantities was read for absorbance at 540nm.  A set of D (+) glucosamine solutions (1-
200µg) was used to produce a standard curve, and all values were normalized to their 
respective dry tissue weights.  It was previously determined that resulting hexosamine 
values include ~90µg /10mg of non-GAG related hexosamines.  Thus, this assay was 
performed as it has been previously, and this value was subtracted from all data 
[18,30,31,131,132].  Spectrophotometery was performed using the µquant 
spectrophotometer (BIO-TEK Instruments, Winooski, VT). 
 In addition to tissues, hexosamine was also performed on the resulting lysate 
solutions obtained during the enzymatic degradation of GAGs, per section 3.2.3.  
Methods were identical with only one change; the lyophilized solution was acid 
hydrolyzed using only 1 mL of 2 M HCl. (n=6) 
 
3.2.5. GAG Quantification: DMMB Assay 
DMMB assay was performed, as it has been previously, in order to quantify 
sulfated GAGs leached from tissue into the corresponding enzyme or buffer solution as 
outlined in section 3.2.3.  The following were pipetted into the individual wells of a 96 
well plate: 20µL of each sample, 30 µL of PBE buffer (100 mM Na2HPO4), and 200 µL 
of DMMB reagent (40mM NaCl, 40mM glycine, 46 µM DMMB, pH 3.0).  Chondroitin 
sulfate solutions (0 - 1.25µg) were used to produce a standard curve.  The resulting 
purple-like color change was indicative of sulfated GAG presence and was read for 
absorbance at 525 nm.  This is done immediately to avoid degradation of the unstable 
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DMMB dye-GAG complex [30,31,133,134].  Spectrophotometery was performed with 
the µquant spectrophotometer (BIO-TEK Instruments, Winooski, VT). (n=6) 
 
3.2.6. Collagen and Elastin Stability 
Collagen and elastin stability is assessed using resistance of leaflet tissue to 
enzymatic degradation.  Leaflets were cut in half, rinsed in distilled water, blotted dry, 
and then frozen at -80°C.  Samples were then lyophilized for 24 hours and weighed prior 
to treatment with either porcine pancreatic elastase or Type VII collagenase, as described 
previously.  Six half leaflets were placed in either 1.2 mL of 5.0 U/ml elastase (100 mM 
Tris buffer, 1 mM CaCl2, .02% NaN3) or 1.2 mL of 75 U/ml collagenase (50 mM CaCl2, 
.02% NaN3, pH 8.0).  Elastase samples were incubated for 24 hours while collagenase 
samples were subject to 48 hours.  Both groups were carried out at 37ºC under constant 
shaking at 650 RPM.  Samples were then removed from solution, rinsed, blotted dry, and 
frozen at -80ºC.  They were then lyophilized and the final dry weight was taken.  This 
weight along with initial dry weight was used to determine the percent weight loss. (n=6) 
 
3.2.7. Differential Scanning Calorimetry 
Differential scanning calorimetry (DSC) was used to determine the collagen 
denaturation temperatures (Td), previously described as the temperature at the 
endothermic peak [135].  Small (3 – 10 mg) samples were cut from generally the same 
region of different cusps, immediately adjacent to the nodule of arantius.  These samples 
were carefully cut to size to enable them to lie flat within the DSC pans.  Samples were 
then weighed and briefly blotted dry before encasing them within hermetically sealed 
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DSC pans.  In the interest of conserving time, a pilot experiment was run with each group 
to determine an approximate value for Td.  In this pilot run, samples were heated from 
25ºC to 105ºC at 2.5ºC/min.  All subsequent runs were heated at 10ºC/min. until a point 
20ºC before the pilot run Td, at which point a one-minute isothermal was held before 
proceeding to 105ºC at 2.5ºC/min.  The collagen denaturation temperature that was 
recorded was taken from the most extreme value within the endothermic peak.  All 
samples were run on DSC 2910 (TA Instruments, New Castle DE). (n=4) 
 
3.2.8. Neomycin Optimization for NEN treatment 
NEN fixation was performed using various concentrations of neomycin trisulfate 
from 0.05 mM to 2 mM.  EDC and GLUT groups were used as controls.  All tissues were 
then subjected to GAG-degrading enzymes, as outlined in section 3.2.3.  GAG stability 
was assessed by hexosamine assay and DMMB analysis (Sections 3.2.4 and 3.2.5). (n=6) 
 
3.2.9. Histological Assessment 
Radial cusp cross-sections were taken from the cusp center and stored in 10% 
buffered formalin (pH 7.4) until use.  Samples were then embedded in paraffin wax and 
sectioned for light microscopy analysis.  For GAG analysis, alcian blue staining with a 
nuclear fast red counterstain was used, where blue staining is indicative of GAG 
presence.  For calcium analysis, Dahl’s alizarin red staining was used with a light green 
counterstain, where red staining is indicative of calcification.  Digital photographs were 
taken with a Zeiss Axioskop 2 Plus (Carl Zeiss MicroImaging, Inc., Thornwood, NY) in 
conjunction with SPOT Advanced software.  
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3.2.10.    Uniaxial Tensile Testing 
For uniaxial tensile testing, the MTS Synergie 100 (MTS Systems, Eden Prairie, 
MN) was used with a 10 N load cell along with Testworks 4 software.  Sections were cut 
from whole leaflets, approximately 4 mm wide using a rectangular tissue stamp.  Sections 
were taken from the center of the cusps in both the radial and circumferential directions 
and were only cut immediately before they were to be run.  The samples were then placed 
within custom grips that were lined with fine sandpaper to protect the tissue from tearing.  
The tissue was then preloaded to a small tension (0.01 N - radial, 0.1 N – circumferential) 
and the tissue’s dimensions were taken.  The tissue was then stretched at a constant rate 
of 12.5 mm/min and the resulting stress-strain curve was used for analysis. (n=6) 
 
3.2.11.    Rat Subdermal Implantation 
All tissues were rinsed thoroughly through three changes of sterile saline for 30 
minutes each and remained in sterile saline until implantation.  Male juvenile Sprague-
Dawley rats (35-40g, Harlan Laboratories, Indianapolis, IN) were anesthetized by 
inhalation of 3% isoflurane gas.  Two incisions were made on the dorsal side of each rat, 
one on each side of the sagittal plane, and the skin was carefully lifted up to form a 
pocket.  Cusps were blotted dry and positioned in the pockets to lie as flat as possible. 
Incisions were closed using surgical staples and tissues were retrieved at three weeks.  
Half of each cusp was used for hexosamine analysis (section 3.2.4) and the other half was 
analyzed for mineral content (section 3.2.12).  Small middle sections were taken for 
histology and immediately immersed in 10% buffered formalin.  All other samples were 
immediately put on dry ice and frozen at -80ºC as soon as possible. (n=10) 
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3.2.12.    Calcium and Phosphorus Analysis 
Sample Preparation: First, samples were lyophilized for 24 hours and then weighed.  
Tissues were then acid hydrolyzed in 2 mL of 6N Ultrex II HCl for 20 hours at 95ºC.  
Samples were then dried under nitrogen and resuspended in 1 mL of 0.01 N Ultrex II 
HCl.  Only small amounts of the sample are used for both calcium and phosphorus 
assays.  Dilution is used to bring samples near the range of the standard curve for each 
analysis. 
 
Calcium and Phosphorus Analysis: A small amount of each sample was used to make a 
100x dilution in distilled water and Clemson University faculty performed calcium and 
phosphorus analysis at the Clemson University Agricultural Service Laboratory.  
Analysis was performed using the Spectro Arcos ICP Spectrometer (SPECTRO 
Analytical Instruments, Kleve, Germany).  Dilution ratios were used to determine the 
total mineral content of the sample and values were normalized to the dry tissue weight. 
 
3.2.13.    Storage Studies 
The GAG content of leaflets was analyzed using hexosamine assay (section 3.2.4) 
after two, four, and six months of storage at room temperature.  All valves were stored in 
the respective final solutions that were used in their fixation process.  Short-term storage 
effects on resistance to enzymatic digestion of GAGs were also tested. (n=6) 
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3.2.14    Statistical Analysis 
 
All results are expressed as the mean ± standard error of the mean (SEM).  All 
statistical analysis was performed using single factor analysis of variance (ANOVA). 
Differences between the means were determined using least-significant difference with a 
significance level of α = 0.05. 
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4. RESULTS 
4.1. Neomycin Optimization for NEN Treatment 
To determine the most effective concentration of neomycin to use with the NEN 
treatment, porcine aortic valve leaflets were crosslinked by NEN using various 
concentrations of neomycin ranging from 0.05 mM to 2 mM.  These tissues were then 
assessed for resistance to GAG degrading enzymes and compared to performance by 
EDC and GLUT groups.  Hexosamine and DMMB analysis were performed after enzyme 
digestion was completed.  It is important to note that the hexosamine assay measures 
non-sulfated and sulfated GAGs, while the DMMB assay is only capable of quantifying 
sulfated GAGs.   
Hexosamines remaining in the tissue were measured and all concentrations of 
neomycin above 0.5 mM in the NEN groups retained high amounts of GAGs within the 
tissues (Figure 4.1).  Low neomycin concentration NEN groups (0.05 mM – 0.25 mM) 
exhibited significantly lower GAG levels for both buffer and enzyme treatments with no 
significant difference between the two.  GLUT offered the least resistance to GAG loss 
with only 79.48 + 17.09 µg GAGs / 10 mg dry tissue remaining after enzymatic digestion 
compared with 141.54 + 11.14 µg GAGs / 10 mg dry tissue remaining after storage in 
buffer.   All GAG digested NEN groups with higher than a 0.5 mM neomycin 
concentration yielded significantly higher tissue GAG contents than both GLUT and 
EDC (p<0.03).  EDC offered some protection against enzymatic attack preserving an 
average of 40.68 + 30.82 µg GAGs / 10 mg dry tissue more than GLUT (p=0.03).  The 
0.5 mM neomycin was the optimal concentration to fully preserve GAGs, exhibiting an 
average of 104.4 + 30.41 µg more GAGs / 10 mg dry tissue than GLUT (p=0.001). 
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Figure 4.1: Quantification of GAGs remaining in the tissue after GAG digestion by 
hexosamine assay. “Red star” indicates significant difference between digested and 
undigested tissue (p<0.05, n=6 per group). 
 
Hexosamine assay was also performed on the solutions that were used to digest 
the tissues (Figure 4.2), and general trends appeared to be the same.  No significant 
differences were detected in the GAG levels of the buffer solutions between any groups.  
The 0.5 mM NEN treatment again seemed to be optimal, losing negligible amounts of 
GAGs to enzymatic attack.  Differences from both 1 mM and 2 mM NEN groups were 
not significant.  Significant differences in the amount of GAGs lost between EDC and 
low concentration NEN groups (0.05 – 0.25 mM) were not found.  This suggests that 
such low neomycin concentrations add little GAG protective effect.  The EDC group 
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seemed to offer some resistance to enzymatic degradation, losing only 10.75 + 4.52 µg 
GAGs/10 mg dry tissue.  On the other hand, GLUT offered the least protection, losing 
69.95 + 4.17 µg GAGs/10 mg dry tissue. 
Figure 4.2: Quantification of GAGs lost into solution during GAG digestion by 
hexosamine assay. “Red star” indicates significant difference between digested and 
undigested tissue (p<0.05, n=6 per group). 
 
DMMB assay was used to further confirm results and was performed on the 
solutions.  With the exception of the GLUT and 0.5 mM NEN groups, all other tissues 
subjected to GAG degrading enzymes lost significantly more sulfated GAGs into solution 
than those stored in buffer solution.  This suggests protection against enzymatic 
degradation by the 0.5 mM NEN group, considering the small amounts of GAGs lost.  
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However, lack of protection is suggested by the GLUT group as the average GAG losses 
were significantly higher than 0.5 mM NEN, with 25.3 + 6.55 µg /10 mg dry tissue 
(p=0.0015) more sulfated GAGs lost to buffer and 29.27 + 5.94 µg/10 mg dry tissue 
(p<0.001) more lost to enzymatic digestion.  In agreement with hexosamine assay results, 
no significant difference was found between GAGs lost for the low neomycin 
concentration group and the EDC group; suggesting again, that such low neomycin 
concentrations little GAG protective effect.  Once more, the 0.5 mM NEN treatment was 
determined to be the most effective at preventing sulfated GAG loss, losing negligible 
amounts on both accounts.  The 0.5 mM group also preserved 7.52 + 4.86 µg/10 mg 
(p=0.051) more sulfated GAGs than the 2 mM NEN, group when subjected to GAGase. 
Figure 4.3: Quantification of sulfated GAGs lost into solution during GAG digestion by 
DMMB assay. “Red star” indicates significant difference between digested and 
undigested tissue (p<0.05, n=6 per group). 
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The combined results from hexosamine and DMMB assays led to the choice of 
0.5 mM neomycin concentration to represent the NEN group for all other 
experimentation.  The choice of a 0.5 mM neomycin concentration for NEN was further 
verifed by histological evaluation.   Intense blue staining, indicative of GAGs, was seen 
for both GAG-digested and undigested valves in the 0.5 mM NEN group (Figure 4.4).  
EDC again seemed to offer some resistance to GAG digestion as lighter blue staining was 
seen, while GLUT offered the least resistance and demonstrated almost an entire absence 
of blue staining.  Alcian blue staining agrees with the values of Figure 4.3, except for the 
progressive decreases in blue staining that are present in the undigested tissue pictures.  
This is possibly due to excessive time in storage prior to embedding and sectioning, and 
may be indicative of resistance to GAG loss in storage.   
 
Figure 4.4: Histological sections of porcine aortic valve cusps after storage in buffer and 
GAGase (Alcian blue staining, blue indicates the presence of GAGs). [A] NEN – Buffer 
stored [B] EDC – Buffer stored [C] GLUT – Buffer stored [D] NEN – GAG Digested  
[E] EDC – GAG Digested [F] GLUT – GAG Digested 
A  B  C 
D  F E 
  87 
4.2. 1,6-Hexane Diamine as a Control for Neomycin 
Substances with multiple amine functionalities have been commonly used by 
certain groups to enhance EDC/NHS crosslinking.  These molecules perform this 
function by acting as bridge molecules during crosslink formation that lengthen 
carbodiimide-initiated zero-length bonds [116-119]. Neomycin is incorporated to 
carbodiimide crosslinks in the same manner and may similarly result in enhanced 
EDC/NHS crosslinking.  To prove our hypothesis that neomycin, when bound to tissue, 
inhibits enzymatic activity and does not just improves EDC crosslinking, we used 1,6 
hexane diamine as a control.  1,6-hexane diamine is not an inhibitor of GAGase enzymes, 
but provides similar amine functionalities to improve EDC crosslinking. 
1,6-hexane diamine has been previously used as an EDC/NHS crosslink coupler 
and is incorporated into HEX fixation [117].  Since neomycin has three times the amine 
groups per molecule, a triple (1.5 mM) concentration of 1,6-hexane diamine was used to 
provide control for amine functionalities.  HEX and NEN were both subjected to 
enzymatic degradation and GAG retention and losses were analyzed using hexosamine 
assay, DMMB assay and histology. 
NEN was shown to overwhelmingly prevent GAG loss better than HEX.  There 
was no significant GAG loss observed for the digested NEN group, however the HEX 
group showed a significant amount of GAG loss.  The HEX group showed only 75.3 + 
6.02 µg GAGs / 10 mg dry tissue in the GAG digested group compared to 117.44 + 11.14 
µg GAGs / 10 mg dry tissue remaining in the buffer stored group (p=0.01).  The NEN 
group had significantly higher GAG amounts than HEX, with 148.46 + 8.86 µg GAGs / 
10 mg dry tissue remaining after GAGase digestion (p<0.001). 
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Figure 4.5: GAGs lost into solution after enzymatic digestion per section 3.2.3.  [A] 
Sulfated GAGs lost for HEX and NEN as measured by DMMB assay. [B] GAGs lost by 
HEX and NEN as measured by hexosamine assay.  “Red star” indicates significant 
difference between digested and undigested tissue (p<0.05, n=6 per group). 
Figure 4.6: GAGs remaining in NEN and HEX tissue after digestion per section 3.2.3.  
Measured using hexosamine assay.  “Red star” indicates significant difference between 
digested and undigested tissue (p<0.05, n=6 per group). 
B A 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DMMB assay demonstrated that NEN lost only 2.09 + 0.94 µg GAGs / 10 mg dry 
tissue to enzymatic degradation accounting for a loss of only 1.47% + 0.66%, while HEX 
lost 27.25 + 6.16 µg GAGs / 10 mg dry tissue or a loss of 23.2% + 5.25%.  These losses 
between NEN and HEX were significantly different (p=0.01).  This is supported by 
almost identical results from hexosamine assay when performed on the solutions. 
However, results for the NEN group exhibited one discrepancy where significantly more 
GAGs to enzymatic digestion when compared to buffer, 8.07 + 1.39 µg GAGs / 10 mg 
dry tissue compared to 1.78 + 0.63 µg GAGs / 10 mg dry tissue (p=0.02). 
Figure 4.7: Histological sections of porcine aortic valve cusps after storage in buffer and 
GAGase (Alcian blue staining, blue indicates the presence of GAGs). [A] NEN – Buffer 
stored [B] NEN – GAG digested [C] HEX – Buffer stored [D] HEX – GAG Digested  
B A 
D C 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DMMB demonstrated that both fixation methods lost negligible amounts into 
buffer solution. Hexosamine assay performed on the buffer solutions showed higher 
amounts of GAG loss, 1.78 + 0.63 µg GAGs / 10 mg dry tissue lost by the NEN group 
and 2.92 + 0.47 µg GAGs / 10 mg dry tissue lost by the HEX group which were not 
significantly different (p=0.18).  As expected, these losses are extremely small and pale 
in comparison to those lost by enzymatic degradation.  Results obtained from all three of 
the performed assays agree and alcian blue staining, as seen in Figure 4.7, visually 
supports these trends. 
 
4.3. GAG Loss During Storage 
The effects of valve tissue storage on GAG loss were tested.  Prior to storage all 
groups demonstrated similar levels of GAGs within the tissue with no significant 
differences detected.  After two months of storage, only GLUT lost a significant amount 
of GAGs (p<0.001).  GLUT valves lost an average of 53.59 + 19.52 µg GAGs / 10 mg 
dry tissue in the first two months of storage.  After four months of storage there was little 
change for any groups when compared to data from the two-month storage time point, 
with no significant differences detected.  After 6 months of storage both GLUT and EDC 
received sharp drops in average GAG levels.  From 4 to 6 months storage, EDC lost an 
astounding 108.06 + 27.19 µg GAGs / 10 mg dry tissue (p=0.005) while GLUT lost 
80.23 + 9.82 µg GAGs / 10 mg dry tissue (p<0.001).   
Overall, NEN experienced no significant loss after 6 months of storage when 
compared to the initial time point, suggesting full protection against GAG loss due to 
storage.  After 6 months of storage, EDC lost 118.34 + 33.3 µg GAGs / 10 mg dry tissue 
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overall, which is equivalent to 76 + 21.4% loss of all tissue GAGs.  GLUT experienced 
similar catastrophic GAG loss after 6 months of storage, although the leaching of GAGs 
in the GLUT group started as soon as 2 months.  When compared to the initial time point, 
GLUT lost 125.77 + 22.28 µg GAGs / 10 mg dry tissue or 88.9 + 15.7% of all tissue 
GAGs.  This same loss was seen visually using alcian blue staining where the GLUT 
group displayed almost a complete lack of blue stain.  Matching hexosamine assay 
results, EDC showed light blue staining suggesting partial GAG preservation and the 
NEN group demonstrated superior preservation of GAGs after 6 months of storage. 
 
Figure 4.8: GAGs remaining in NEN, EDC, and GLUT tissue after 0, 2, 4, and 6 months 
of storage as measured using hexosamine assay.  “Red star” indicates significant 
difference between the two groups (p<0.05, n=6 per group). 
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 The effect of short-term storage on resistance to enzymatic degradation of GAGs 
was also tested.  Enzymatic digestion was performed on tissue after two months of 
storage.  The NEN group demonstrated high resistance to GAG degradation losing only 
negligible GAG amounts into solution (Figure 4.10) and retaining high amounts in the 
tissue (Figure 4.11).  The EDC group offered some protection against enzymatic attack, 
losing only 5.33 + 1.65 µg GAGs / 10 mg dry tissue.  The GLUT group offered the least 
resistance to GAG loss from both treatments, losing 8.87 + 0.93 µg GAGs / 10 mg dry 
tissue into buffer solution and significantly more, 29.75 + 4.04 µg GAGs / 10 mg dry 
tissue to enzymatic attack (p<0.001).  GLUT exhibited the least amount of GAGs 
remaining in the tissue, much less than NEN, with 42.87 + µg GAGs / 10 mg dry tissue 
less in the buffer group and 68.19 + 15.54 µg GAGs / 10 mg dry tissue less when 
subjected to GAGase. 
Figure 4.9: Histological sections of porcine aortic valve cusps after 6 months of storage 
(Alcian blue staining, blue indicates the presence of GAGs). [A] NEN – 6 months of 
storage  [B] EDC – 6 months of storage [C] GLUT – 6 months of storage 
 
 
A  B  C 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Figure 4.10: Quantification of sulfated GAGs lost into solution during GAG digestion by 
DMMB assay after two months of tissue storage. “Red star” indicates significant 
difference between digested and undigested tissue (p<0.05, n=6 per group). 
 
Figure 4.11: Measure of GAGs remaining in the tissue after GAG digestion by 
hexosamine assay after two months of storage.  “Red star” indicates significant difference 
between digested and undigested tissue (p<0.05, n=6 per group). 
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4.4. Resistance to Collagenase 
Resistance to collagenase digestion is used as a common measure of collagen 
stability within BHV tissues.  Tissues were subjected to collagenase digestion as per 
section 3.2.6 and % weight loss after treatment was used to assess performance (Figure 
4.12).  The HEX group was used as a control for similar reasons that were explained in 
section 4.2.  HEX was used to determine if the amine groups or bridging effects were 
responsible for enhanced crosslinking instead of functions specific to neomycin.  There 
was no significant difference in percent weight lost between GLUT, HEX and NEN 
groups which lost 16.86 + 0.94%, 17.16 + 1.66% and 17.9 + 1.82% weight after 
treatment, respectively.  This suggests similar collagen stability between these 3 groups, 
but all of these groups exhibited significantly lower weight loss than the EDC group 
(p<0.013).  The NEN group lost 5 + 2.74 % less weight than the EDC group (p=0.001). 
Comparatively, the HEX group also lost 5.75 + 2.58% less weight than the EDC group 
(p=0.013).  This suggests that neomycin enhances collagen stability in EDC/NHS 
crosslinked tissue.  However, considering that the HEX group also experienced similar 
improvements, this suggests that effects of amine bridging enhance the collagen stability 
of EDC/NHS crosslinked tissue instead of functions specific to neomycin. 
 
4.5. Resistance to Elastase 
Resistance to elastase was used as a measure of elastin stability as per section 
3.2.6 and % weight loss was used to assess performance (Figure 4.13).  The HEX group 
was used as a control for the same reasons described in sections 4.2 and 4.4 above.  The 
NEN and GLUT groups had statistically insignificant differences in percent weight loss 
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at 26.69 + 0.68% and 27.36 + 0.62%, respectively.  The NEN group exhibited 5.72 + 
1.78 less percent weight loss than EDC (p=0.002), suggesting that neomycin improves 
the elastin stability of EDC/NHS crosslinked tissue.  Also, given that NEN demonstrated 
3.81 + 1.83 less percent weight loss than HEX, this suggests that the improved stability is 
due to functions specific to neomycin and not due to effects from amine coupling. 
Figure 4.12: Results of collagenase digestion per section 3.2.6 expressed as % weight 
loss.  “Red Star” indicates significant difference from EDC (p<0.05, n=6 per group). 
Figure 4.13: Results of elastase digestion per section 3.2.6 expressed as % weight loss. 
“Red Star” indicates significant difference from EDC, “Green Star” indicates significant 
differences from HEX (p<0.05, n=6 per group). 
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4.6. Differential Scanning Calorimetry (DSC) 
The collagen denaturation temperature (Td) for various tissue groups was assessed 
as discussed in section 3.2.7.  All groups exhibited a sufficiently high degree of 
crosslinking as the Td for EDC and NEN were significantly higher than that of GLUT 
(p<0.001).   The Td of GLUT was only measured to be 86.59 + 0.56 °C, while EDC and 
NEN were measured as 92.83 + 0.36 °C and 93.6 + 0.38 °C, respectively (Figure 4.14).  
The insignificant difference between the measured Td’s for the EDC and NEN groups 
suggests that neomycin has no affect on the degree of crosslinking for EDC/NHS fixed 
cusp tissue.  Examples of DSC curves that were obtained are displayed in Figure 4.15, the 
endothermic peaks are highlighted and the Td was taken at the point of minimum value 
within this peak.  Visual overview of these DSC curves, demonstrates the similarities in 
collagen thermal stability between EDC and NEN groups. 
Figure 4.14: Collagen denaturation temperatures as measured by differential scanning 
calorimetry (DSC).  “Red Star” signifies significant difference when compared to GLUT. 
(p<0.05, n=4 per group). 
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Figure 4.15: Overlay of example DSC curves for each tissue group.  Data was obtained 
per section 3.2.7.  Endothermic peaks where Td was recorded are within the red circle. 
 
4.7. NEX as a Control for Formaldehyde Crosslinking 
Formaldehyde is a well-known tissue fixative that is used widely throughout 
laboratory practices.  As discussed in section 1.6.1, formaldehyde is capable of forming 
crosslinks with collagen molecules using available amine functionalities.  These 
crosslinks may affect resistance to collagenase treatment as well as collagen thermal 
stability.  In order to determine these effects, the NEX group (section 3.2.2) was used as a 
control for both collagenase and DSC experiments (sections 3.2.6 and 3.2.7).   
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Results after collagenase treatment showed no significant difference in the 
percentage of weight loss amongst any groups (Figure 4.16).  Weight loss by the NEX 
group was 13.02 + 1% while the NEN group lost 14.01 + 1.76% weight after collagenase.  
This suggests that formaldehyde crosslinking had no affect on the enzymatic stability of 
collagen.  On the other hand, formaldehyde was found to have an effect on the degree of 
crosslinking within the tissue.  
This effect was characterized by measuring the average collagen denaturation 
temperature using DSC (Figure 4.17).  The NEX group was found to have a much lower 
Td than the NEN group (p<0.001), measured at 87.225 + 0.45°C.  This was 6.38 + 0.82 
°C lower than the measured Td for the NEN group at 93.6 + 0.38 °C and suggests that 
formaldehyde greatly increased the degree of crosslinking within cusp tissue.  However, 
the Td of NEN was not found to be significantly different from GLUT suggesting that the 
NEN treatment without formalin (NEX) may provide a sufficient degree of crosslinking 
for use in BHVs.  A visual overview of this can also be seen through the similarities 
between the DSC curves of GLUT and NEX displayed in Figure 4.15. 
Figure 4.16: Results of collagenase digestion per section 3.2.6 expressed as % weight 
loss.  No significant differences were detected (p<0.05, n=6 per group). 
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Figure 4.17: Collagen denaturation temperatures as measured by DSC (section 3.2.7).  
“Red Star” signifies significant difference from NEN (p<0.05, n=4 per group). 
 
4.8. Rat Subdermal Study: GAG Preservation and Calcification 
Rat subdermal implantation was performed to study calcification and in vivo 
GAG stability.  The amount of GAGs remaining in the tissues after explant was measured 
by hexosamine assay and verified visually using histology.  The NEN group exhibited the 
highest GAG levels remaining within the tissue at 152.74 + 16.42 µg GAGs / 10 mg dry 
tissue.  This is similar to levels measured from in vitro studies after storage in buffer, 
suggesting near full protection against GAG loss from in vivo degradation.  This was 
significantly higher than levels for both the EDC and GLUT groups, which measured 
112.57 + 8.95 µg GAGs / 10 mg dry tissue and 97.64 + 6.50 µg GAGs / 10 mg dry tissue, 
respectively.  There was no significant difference detected between GAG amounts in the 
EDC and GLUT tissues (p=0.20).  The NEN group preserved 40.17 + 25.37 µg GAGs / 
10 mg dry tissue more than the EDC group, which was found to be significant (p=0.045).  
This suggests that the addition of neomycin into EDC/NHS crosslinked tissue provides 
additional protection against GAG degradation from in vivo sources. 
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Figure 4.18: Measure of GAGs remaining in the tissue after rat subdermal implantation 
by hexosamine assay.  “Red star” indicates significant difference from GLUT.  “Green 
Star” signifies significant differences from EDC.  (p<0.05, n=10 per group). 
Figure 4.19: Histological sections of porcine aortic valve cusps after rat subdermal 
implantation (Alcian blue staining, blue indicates the presence of GAGs).  [A] GLUT   
[B] EDC  [C] NEN.  
 
 Visual review of histology sections largely corresponds with hexosamine assay 
results, except that EDC is suggested to offer slight improvements on GAG retention.  
Again, this may be due to brief storage in formalin prior to embedding and sectioning.  
However, it is still very clear that NEN tissues retained a superior amount of GAGs as 
indicated by intense blue staining, while GLUT exhibits very light blue staining. 
A  C B 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Rat subdermal implantation was also used to study the effects of the various 
fixation methods on calcification.  Calcium and phosphorus levels were measured after 
tissues were explanted, as calcium and phosphate are key players in BHV mineralization 
[5,6,78,79,147].  No significant differences were detected between any groups when 
analyzed for calcium content.  Calcium levels for the EDC and NEN groups were found 
to be similar at 63.96 + 6.12 µg/mg dry tissue and 64.16 + 11.95 µg/mg dry tissue, 
respectively.  These values were both lower than the GLUT group at 83.60 + 6.12 µg/mg 
dry tissue, but not significantly so, with p=0.115 when compared to EDC and p=0.199 
when compared to NEN (Figure 4.20).   
Measured phosphorus content in the cusps demonstrated an identical trend.  There 
were no significant differences observed between any of the groups although the EDC 
and NEN groups appeared to be slightly lower than GLUT (Figure 4.20).  GLUT 
phosphorus levels were measured as 41.2 + 2.61 µg/mg dry tissue, while EDC and NEN 
groups seemed to be lower on average (p=0.06 and p=0.14, respectively).  EDC 
phosphorus levels were measured as 29.9 + 4.52 µg/mg dry tissue and NEN was found to 
be 30.4 + 5.89 µg/mg dry tissue.   
The molar ratios of calcium to phosphorus were also calculated to further 
characterize the tissue mineralization.  The Ca:P molar ratios were similar for all groups  
at 1.57, 1.65, and 1.63 for GLUT, EDC, and NEN groups, respectively.  This suggests 
similar progression of calcification for all groups and is indicative of hydroxyapatite 
formation, which has a Ca:P molar ratio of 1.67.  Despite the appearance of lower 
mineralization in EDC and NEN, no differences found were significant.  This suggests 
that NEN treatment did not inhibit BHV cusp mineralization. 
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Figure 4.20: Calcium and phosphorus content of cusp tissue after rat subdermal 
implantation as measured using atomic absorption spectroscopy (section 3.2.12).  No 
significant differences were detected for any groups.  (p<0.05, n=10 per group). 
 
 Histology was used to visually analyze the presence of calcification using Dahl’s 
alizarin red stain (Figure 4.21).  Observed tissue sections exhibited varying amounts of 
calcification, as indicated by the presence of red staining.  There appeared to be no 
noticeable difference in the location of calcified areas, and the morphology of calcified 
regions for all groups appeared to be very comparable to one another.  This is expected as 
the modes of mineralization where suggested to be the same, with hydroxyapatite 
formation indicated for all groups.  Visual analysis of all tissue section supports the 
hypothesis that mineralization for all groups progressed similarly. 
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Figure 4.21: Histological sections of porcine aortic valve cusps after rat subdermal 
implantation (Dahl’s alizarin red staining, red indicates the presence of calcification).  
[A] GLUT [B] EDC [C] NEN [D] GLUT [E] EDC [F] NEN. 
 
4.9. Characterization of Tissue Mechanics: Uniaxial Tensile Testing 
4.9.1.    Stiffness (Modulus of Elasticity) 
Modulus of elasticity (E) was used as a measure for tissue stiffness.  Uniaxial 
tensile testing was performed on all groups and the slope of the resulting stress-strain 
curve was utilized to assess tissue stiffness.  NEN was compared to GLUT and untreated 
tissue (FRESH) for baseline controls.  NEN was also compared to EDC to determine the 
effects of neomycin and, likewise, was evaluated against NEX to ascertain the effects of 
formaldehyde crosslinks.  Stiffness was tested in both the radial and circumferential 
directions, and both the low-end and high-end stiffness responses were recorded    
(Figure 22 and Figure 23). 
A  B  C 
E D  F 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 The stiffness of GLUT tissue was significantly higher than FRESH on all 
accounts, as expected (p<0.025).  Also, stiffness in the circumferential direction was 
found to be much higher than in the radial direction for every treatment group.  The 
stiffness of NEN tissue was found to be statistically higher than FRESH on all accounts 
(p<0.001), except for the high-end response of the radial direction, which appeared to be 
a very close approximation to the E of FRESH tissue (p=0.505).  Stiffness for GLUT was 
found to be significantly higher than NEN for the high-end response in both the radial 
and circumferential direction (p<0.026).  High-response E values for the NEN group 
were 49.59 + 11.93% lower than GLUT in the circumferential direction and 30.91 + 
9.53% lower in the radial direction.  On the other hand, for the low-end response, no 
significant difference was detected between NEN and GLUT groups for either direction. 
 Neomycin was only found to have a significant effect on stiffness for the low-end 
response in the circumferential direction.  In this one case, E for EDC was measured to 
be 32.88 + 11.58% lower than NEN (p=0.044).  This is at odds with results for all other 
responses, where a trend seemed to form in which NEN stiffness appeared to be slightly 
lower than EDC, although not significantly so.  Formaldehyde only seemed to play a role 
in stiffness for the low-end response, as no significant differences were found between 
NEN and NEX for the high-end E values.  Low-end response E values for NEX were 
found to be significantly lower than NEN for both directions (p<0.048).  E for NEX was 
measured to be 56.07 + 10.91% lower in the circumferential direction and 28.28 + 
10.23% lower in the radial direction.  Overall, GLUT tissues appeared to be the stiffest 
while FRESH tissues were, by far, the least stiff.  Stiffness for NEN tissue seemed on the 
middle ground, lower than or equal to GLUT and higher than or equal to FRESH. 
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Figure 4.22: Modulus of Elasticity for porcine aortic valve cusps for the circumferential 
direction.  [A] High-end response.  [B] Low-end response.  “Red Star” indicates 
significant difference from GLUT.  “Green Star” indicated significant difference from 
FRESH (p<0.05, n=6 per group). 
 
 
 
 
 
 A 
 B 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Figure 4.23: Modulus of Elasticity for porcine aortic valve cusps for the radial direction. 
[A] High-end response.  [B] Low-end response.  “Red Star” indicates significant 
difference from GLUT.  “Green Star” indicated significant difference from FRESH 
(p<0.05, n=6 per group). 
 
 
 
 
 
 A 
 B 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4.9.2.    Extensibility 
For this study, extensibility is defined as the amount of strain the tissue allows 
before transition to the collagen dominated high-end stiffness response.  Uniaxial tensile 
testing was performed on all groups, and the results from the stress-strain curve were 
extrapolated to find extensibility.  The slope line used to determine the high-end modulus 
of elasticity was extended down to the x-axis, and the strain at this point was recorded as 
the transition point, or extensibility (Figure 4.24).   
Extensibility in the radial direction was much higher, overall, than in the 
circumferential direction (Figure 4.25).  This is expected as the tissue in the aortic valve 
cusp has adapted to be much more yielding in the radial direction to aid in proper 
function.  Extensibility of the tissue seemed to decrease after GLUT fixation, with 
average GLUT extensibility values measuring 12.08 + 10.4% less than FRESH in the 
radial direction and 16.31 + 3.17% less in the circumferential direction.  However, only 
the difference in the circumferential direction was found to be significant (p<0.001). 
None of the EDC/NHS crosslinked groups were found to have any statistically 
significant change in circumferential extensibility when compared to FRESH tissue 
(p>0.12).  All EDC/NHS crosslinked groups experienced increases in extensibility in the 
radial direction, although EDC was not found to be statistically different from FRESH 
(p=0.083).  Extensibility for NEN was measured to be 27.62 + 13.98% higher than 
FRESH (p=0.020) in the radial direction and 39.7 + 7.36% higher than GLUT (p<0.001).  
Formaldehyde crosslinking appears to play no role in these measured extensibilities, as 
no statistically significant differences in extensibility were found in either direction 
between NEX and NEN. 
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Figure 4.24: Stress-strain curve for GLUT tissue in the radial direction.  The point at 
which the thin red line crosses the x-axis was recorded as the strain for extensibility. 
Figure 4.25: Extensibility for various groups in both the radial and circumferential 
direction.  “Red Star” indicates significant difference from GLUT.  “Green Star” 
indicates significant difference from FRESH.  (p<0.05, n=6 per group) 
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4.9.3.    Stress-Strain Relationship Observations 
During stiffness and extensibility analysis, a unique attribute of certain stress-
strain curves was noticed that distinguishes the different groups from one another.  As 
mentioned previously in section 1.5.3, the stress-strain relationship for heart valve cusp 
tissue is highly non-linear and clearly separated into two regions.  This was also verified 
firsthand during uniaxial tensile testing on FRESH and GLUT tissue, where both groups 
were found to express this relationship exactly (Figure 26A).  However, all other groups 
were found to demonstrate an additional third region (Figure 26B and 26C).   
The third region appeared at the transition between the low-end response and the 
high end-response, but only in the radial direction.  Instead of the normal bend during 
transition that is seen in GLUT and FRESH stress-strain curves, a clear “hump” is seen in 
the stress-strain curve for all EDC/NHS crosslinked groups in the radial direction.  This 
hump is noticeable in the EDC group, but is much more pronounced in the NEN and 
NEX groups.  This suggests that not only does EDC/NHS crosslinking play a role in this 
unique response, but neomycin does as well. 
Figure 4.26: Comparing a normal two-region stress-strain curve two those with a third-
region (This region is circled in red).  [A] FRESH [B] EDC [C] NEN. 
 B   C  A 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5. DISCUSSION 
Calcification and non-calcific tissue damage are the two primary causes of 
structural deterioration that lead to clinical BHV failure [5,76].  Collagen, elastin, and 
remnant cell debris within BHV tissue are all recognized nucleation sites for calcification 
[5,12].  Elastin calcification is thought to occur regardless of chemical modification [12]; 
however, there is evidence that mineralization at other sites is potentiated by 
glutaraldehyde treatment [137,138].  Calcification is also exacerbated at sites of increased 
mechanical stress, which highlights another major contributor to BHV failure, 
mechanically induced tissue damage [124,127]. 
Non-calcific structural damage has been shown to occur independently of 
calcification and roughly 90% of porcine aortic valve BHVs fail from structural damage 
while showing little to no signs of calcification [76,81].   Degeneration in cyclic fatigue 
testing suggests that mechanical stresses are a major source of non-calcific tissue damage 
[124].  This may be due in part to glutaraldehyde fixation, which increases stiffness, 
reduces extensibility, and fails to preserve GAGs within cusp tissue.   
GAG loss has been connected to both tissue buckling and delamination and has 
been documented in failed BHVs [19,31,77].  Even minor deviations from normal 
biomechanics or tissue stress levels can lead to premature BHV dysfunction since 
damage progresses unrestrained without the ability for BHV tissues to repair.  This is 
substantiated by cases of BHV failures that occurred as a result of only minor design 
changes [139].  Therefore, the loss of GAGs in BHVs may indirectly lead to the 
accumulation of collagen damage over time, ultimately contributing to BHV failure.   
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5.1. GAGs in BHVs 
GAGs in BHV cusp tissue are primarily associated with the PGs versican and 
decorin [19,131].  The functions of decorin are not fully understood, but have been 
proposed to include roles in collagen fibril formation and organization as well as roles in 
elastogenesis [140,141].  These functions cater to viable tissues, and the loss of these 
GAGs may not significantly impact BHVs durability.  Versican aids in tissue hydration, 
helps control internal shear stress levels, absorb compressive loads, and promotes 
smoother bending which helps prevent tissue buckling [31,140].  Versican also contains 
elastin binding regions that may deter elastin calcification.  This further establishes the 
case that GAGs associated with versican play a much larger role in BHV durability [19]. 
  
5.2. GAG Loss and Consequences 
GAGs associated with decorin are more likely to be preserved by glutaraldehyde 
due to a relatively unblocked protein core that is available for crosslinking.  On the other 
hand, GAGs related to versican are thought to remain unbound since the numerous 
attached GAG chains hinder reaction by protein core with crosslinkers.  Flourophore-
assisted carbohydrate electrophoresis performed on clinical BHVs that failed due to 
structural deterioration helped confirm these hypothesis [19].  Highly reduced levels of 
chondroitin-6-sulfate were expressed, a GAG normally associated with versican [19].  
Conversely, a high proportion of remaining GAGs were found to be chondroitin-4-
sulfate, which is commonly associated with decorin [19].  This is consistent with the 
theory that GAG loss facilitates BHV failure, since versican loss would be much more 
detrimental than decorin loss.   
  112 
Versican expression is highest in the spongiosa, and GAG loss associated with 
versican leads to thinning of this tissue layer, a phenomenon observed in failed, explanted 
BHVs [19,131].  The spongiosa is responsible for providing lubrication that reduces shear 
stresses formed between the fibrosa and ventricularis that could otherwise lead to 
delamination.  Cyclic flexural fatigue demonstrated that delamination of the tissue layers 
was the primary cause of BHV failure beginning at 10 million cycles [77].  Taken 
together with another study that demonstrated that the majority of GAGs are loss in 
glutaraldehyde fixed tissues by 10 million cycles, this advocates the role of GAGs in 
preventing failure from delamination [15].  The onset of GAG loss at 10 million cycles is 
also prior to collagen structural damage, which makes GAG loss a possible contributor to 
structural deterioration [15].  GAG depleted tissues have also demonstrated greater tissue 
buckling depth as well as increased flexural rigidity, both undesirable traits [18,31].  This 
further demonstrates the importance of GAGs in BHV tissue, and again implicates 
versican as a major source of GAG loss. 
GAGs are not only lost during implantation and fatigue, but are also lost during 
preparation and storage [31,75].  Loss can occur from the liberation of unbound GAGs, 
but is also driven by enzymatic degradation since glutaraldehyde does not fully inactivate 
GAG-degrading enzymes [75,83,142].  In addition to biomechanical repercussions, GAG 
loss has also been suggested to impact BHV durability in other ways.  The bulky nature 
of versican has been stated to offer protection from proteolytic degradation by steric 
interference [136], however this has been disputed [18].  Moreover, GAG loss was shown 
to stimulate calcification in the rat subdermal model [86], and conversely GAG binding 
was demonstrated to hinder mineralization [88,133], but this also faces debate [18]. 
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5.3. GAG Preservation 
Various fixation methods have been used to chemically stabilize GAGs to 
improve preservation during storage, fatigue, and implantation.  The uses of EDC/NHS 
and sodium metaperiodate have both demonstrated improved GAG stabilization when 
compared to glutaraldehyde treated tissues [88,132].  However, they were also 
established to be only partially effective at protecting GAGs from enzymatic degradation.  
Considering the fact that GAG degrading enzymes infiltrate BHV tissues after 
implantation [25], additional protection against enzymatic degradation is needed. 
Neomycin was employed by our lab using various fixation strategies and offered 
improved GAG stability in tissues that were subjected to enzymatic degradation 
[133,UD*].  The NEG group (Neomycin + EDC/NHS + Glutaraldehyde) demonstrated 
superior GAG preservation but excessive crosslinking sacrificed the compliancy of cusp 
tissue, which was demonstrated by biaxial and uniaxial analyses [30,133,UD].  The NG 
group (Neomycin + Glutaraldehyde) demonstrated better compliancy along with 
improved GAG preservation, but still lost GAGs during storage as lack of covalent GAG 
crosslinking led to loss by leaching. [UD].  NG and NEG were both also subject to 
calcification in the rat subdermal model, presumably, due to the use of glutaraldehyde 
[133,UD].  We proposed the use of formaldehyde instead of glutaraldehyde, would yield 
tissues with better mechanical properties since formaldehyde storage has previously been 
demonstrated to better maintain tissue compliance [143].  Additionally, formaldehyde 
performs many of the beneficial functions of glutaraldehyde, but may produce tissues 
with reduced tendency to calcify.  Therefore, we proposed that the use of EDC/NHS 
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fixation in combination with neomycin and formaldehyde would provide the desired 
stability to ECM components without sacrificing tissue compliance.   
 
5.4. Resistance to Enzymatic GAG Digestion 
Past fixation strategies, NEG and NG, have utilized a 1 mM concentration of 
neomycin to effectively shield GAGs from in vitro enzymatic degradation [133,UD].  
The optimal neomycin concentration for the NEN treatment was found to be 0.5 mM, 
which is in close agreement with unpublished data for both NEG and NG fixation 
methods.  The NEN group demonstrated complete resistance to GAGase digestion noting 
no difference in the amount of GAGs remaining in cusp tissue after GAGase treatment.  
GAG preservation was confirmed by analyzing the GAG content of the solutions, as well 
as through histology.  These results are similar to those previously found using NEG 
fixation suggesting that the use glutaraldehyde is unnecessary to provide neomycin and 
GAG stability when used with EDC and NHS [133]. 
EDC/NHS crosslinking, without the addition of neomycin, offered some 
protection against in vitro enzymatic degradation, although not as complete as NEN 
fixation.  Carboxyl groups on the hexuronic acid repeats of GAGs have been shown to be 
the initiating site for enzymatic attack by GAGases, and are the same groups used by 
EDC and NHS for crosslink formation in NEN treated tissues [144].  Blockage of these 
sites was shown to prevent enzymatic hydrolysis of β-(1,4) glycosidic linkages, which are 
present on both hyaluronan and chondroitin sulfate (Figure 3B) [144].  According to 
enzyme supplier’s website (www.sigmaaldrich.com), both the hyaluronidase and 
chondroitinase used for these studies are capable of initiating cleavage at β-(1,4) 
  115 
glycosidic linkages.  Therefore, steric interferences caused by these crosslinks are likely 
the cause of EDC treated tissue’s resistance against GAGase degradation.  However, 
protection against GAG loss is only partial due to incomplete blocking of the activation 
site along with insufficient crosslinking to safeguard all associated carboxyl groups. 
All neomycin containing groups, NEN, NEG, and NG, have demonstrated 
protection against both chondroitinase and hyaluronidase [133,UD].  This is probably due 
to the fact that both enzymes exhibit similar cleavage mechanisms.  According to the 
enzyme supplier’s website, as stated above, both enzymes are capable of hydrolyzing β-
(1,4) glycosidic linkages on hyaluronan and chondroitin sulfate (Figure 3B).  Protection 
against both hyaluronidase and chondroitinase is critical for the full preservation of 
versican aggregates in the spongiosa since they contain large amounts of both CS and HA 
[17,19,131].  These aggregates have been established as a significant source of GAG loss 
[19] and are likely the most important GAG structures when concerning protection 
against mechanical fatigue damage in BHVs [18,30,31]. 
Protection against the enzymatic degradation of GAGs that is offered by 
neomycin carried over into an in vivo model with the NEN treated tissues demonstrating 
full GAG preservation after rat subdermal implantation for 3 weeks.  There appeared to 
be no significant amount of GAGs lost during 3 weeks of implantation when compared to 
baseline GAG content for undigested tissues.  This mirrors results previously obtained for 
the NEG group, which demonstrated similar GAG preservation after 3 weeks of rat 
subdermal implantation [133].  Again, this suggests that the use of glutaraldehyde 
treatment is unnecessary to provide neomycin and GAG stability for tissues crosslinked 
using EDC and NHS. 
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5.5. Controls for Neomycin 
The inhibitory effect of neomycin on GAG degrading enzymes has previously 
been demonstrated by both NEG and NG fixation methods [30,UD].  In order to verify 
that neomycin was responsible for inhibiting GAGase activity, the GAG preserving 
characteristics of 2-deoxystreptamine dihydrobromide (DOS), a molecule with 
comparable structure to neomycin, were evaluated.  Tissues treated with DOS along with 
EDC, NHS, and glutaraldehyde failed to demonstrate matching enzymatic protection 
against GAG loss to that of the NEG group, and exhibited significant amounts of GAG 
loss after GAGase treatment [30].  
 For this study, a triple concentration of 1,6-hexane diamine was used as a control 
for neomycin instead of an equal concentration of DOS.  Previously, 1-6-hexane diamine 
has been used to enhance EDC/NHS crosslinking [117], and a triple concentration was 
used in order to provide a control for the number of provided amine functionalities (HEX 
fixation).  HEX treated tissues failed to provide protection against enzyme-initiated GAG 
loss equal to that of NEN, losing a significant amount of GAGs after GAGase treatment.  
This further demonstrates the GAG preserving properties of neomycin, and rules out the 
contribution of amine functionalities to the protection of BHV tissues against enzymatic 
GAG degradation.   
 
5.6. GAG Preservation During Storage 
BHVs may be stored for up to three years from the moment of sterilization, in a 
clinical setting [145].  During storage for a period up to 5 years, progressive GAG loss 
has been shown to occur in glutaraldehyde treated BHV tissues.  The addition of 
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neomycin to glutaraldehyde was shown to slow the rate of GAG loss during storage, as 
demonstrated by NG fixation for storage up to 400 days [UD].  This demonstrates the 
importance of protection from enzyme-initiated GAG degradation during storage, 
considering that enzymatic activity is not abolished by glutaraldehyde fixation 
[75,83,142].  However, GAG loss was only slowed by neomycin, not prevented, and 
GAGs were still lost due to leaching.  The additional use of EDC/NHS crosslinking 
further preserved GAGs, and NEG treated tissues demonstrated negligible GAG losses 
after 1 year of storage [30].   
NEN treated tissues demonstrated similar characteristics by showing complete 
GAG preservation throughout storage periods spanning 2, 4, and 6 months.  Resistance to 
direct GAGase digestion for the NEN group was also retained after 2 months of storage, 
suggesting that the protective properties of neomycin do not degrade during short-term 
storage.  The effects of further storage on the decay of neomycin’s functions were not 
tested for the NEN group, but a previous study has demonstrated that it still provides total 
protection from direct GAGase digestion after 1 year of storage [30].  
 
5.7. Collagen and Elastin Stability 
Collagen is the most prominent protein in BHV tissue and collagen fibers are 
recognized as the most important structures regarding the overall integrity of BHVs.  The 
most common cause of collagen fiber disruption is non-calcific damage, which can be 
mechanically induced or initiated by enzymatic activity [76,81,83].  Collagen 
crosslinking due to glutaraldehyde fixation helps protect against autolytic degradation 
[5,6].  This may occur during storage and implantation, as active proteolytic enzymes 
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have been noted in BHV tissues after glutaraldehyde fixation [83], and have also been 
found to inhabit clinically explanted BHV tissues [146].   
Resistance to collagenase digestion has previously been used as a measure of 
collagen stability [30] and was also used to assess the viability of NEN treated tissues.  
Tissues crosslinked using the NEN treatment were found to demonstrate similar collagen 
stability to those crosslinked using glutaraldehyde.  Neomycin improved upon the 
collagen stability of EDC/NHS crosslinked tissue, with the NEN group showing less 
weight loss than the EDC group.  However, this is due to the addition of amine 
functionalities into the tissue and not a function specific to neomycin since the use of 1,6-
hexane diamine yielded similar improvement.   Two hypotheses are offered as the reason 
for the enhanced collagen stability offered by neomycin and 1,6-hexane diamine addition:   
• The bridging effect offered by polyamine molecules yields enhanced collagen 
crosslinking via the ability to form different length crosslinks instead of only the 
zero-length bonds formed by EDC and NHS. 
• The addition of more amines into the tissue allows additional crosslinks to be 
formed, which leads to higher stability.  More carboxyl groups are readily 
available on collagen than amine groups [115], leaving the number of amine 
groups on collagen as the limiting factor in the number of possible crosslinks. 
Previous use of 1,6-hexane diamine along with suberic acid, EDC, and NHS has also 
been demonstrated to provide tissues with similar collagenase resistance to that afforded 
by glutaraldehyde [117].  However, this treatment was not equally compared to 
EDC/NHS fixation alone and therefore, enhanced EDC/NHS crosslinking by 1,6-hexane 
diamine could not be confirmed. 
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 Since formaldehyde reacts with free amine groups on collagen molecules, the 
effect of formaldehyde crosslinking on collagen stability was also evaluated.  Despite the 
monofunctional nature of formaldehyde, formaldehyde crosslinks actually provide 
greater resistance to collagenase than the bifunctional glutaraldehyde at a concentration 
of 1% [148].  This is most likely because of deeper penetration into the layers of collagen 
structure allowed by formaldehyde’s small size [148].  The NEX group, identical to the 
NEN group with the omission of formaldehyde, was found to have similar collagen 
stability to NEN treated tissues.  This suggests that formaldehyde does not affect the 
collagenase resistance of tissues crosslinked using EDC, NHS, and neomycin.  
Formaldehyde crosslinks may have no effect because the majority of collagen amines 
have already reacted with EDC and NHS during NEN fixation.  The deeper level 
crosslinks that are afforded by formaldehyde may also be inaccessible to collagenase and 
fail to contribute to enzymatic resistance. 
Assessing the loss of elastin is also important as it may augment the onset of 
collagen damage indirectly through changes to BHV tissue mechanics.  The stability of 
elastin was also measured using resistance to elastase digestion, as done previously [30].  
Like with collagen stability, similar elastin stability by both NEN and GLUT groups was 
observed and the elastin stability of EDC tissue was improved by the addition of 
neomycin.  However, in this case, the action appears to be exclusive to neomycin, as the 
HEX group did not experience the same effect.  The mechanism behind neomycin’s 
protection against elastase digestion is unknown, but was also previously demonstrated in 
NEG and NG crosslinked tissues [30,UD]. 
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5.8. Collagen Denaturation Temperature 
The collagen denaturation temperature (Td) of BHV tissues is an indirect 
measurement of the degree of collagen crosslinking.  The Td for all groups was measured 
using differential scanning calorimetry, which was first described in 1995 [135].  The 
measured Td for GLUT was found to be around 86 °C, which is very similar to previously 
reported values [135].  The measured Td for NEN and EDC were statistically higher than 
GLUT, but not statistically different from one another.  This suggests that neomycin has 
little effect on the thermal stability of collagen structures.   
The large increase in Td for EDC and NEN tissues was found to be a result of the 
contribution from formaldehyde crosslinking.  The small size of the formaldehyde 
molecule allows deep penetration into collagen structures initiating crosslinks all the way 
down at the pentafibril level [148].  The increased amount of crosslinking allowed by 
formaldehyde causes tissues to display a higher Td.   This is consistent with previous 
studies that demonstrated a higher Td for formaldehyde crosslinked tissue than 
glutaraldehyde crosslinked tissue [148].   
The effect of formaldehyde crosslinking was confirmed as the NEX group was 
measured to have a much lower Td than the NEN group.  The measured Td of NEX tissue 
was consistent with previously measured values for EDC/NHS crosslinked tissue [135]; 
further supporting the fact that neomycin does not affect thermal stability.  The Td for the 
NEX group was not statistically different from that of GLUT tissue, suggesting that 
EDC/NHS crosslinking with neomycin provides sufficient crosslinking without the use of 
formaldehyde.   
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5.9. Calcification 
Glutaraldehyde crosslinking has previously been implicated to render BHV 
tissues more conducive to calcification [5,62,78], and alternative crosslinking strategies, 
using EDC and NHS, have demonstrated improved resistance to calcification in the rat 
subdermal model [116,117,119].  Despite this fact, the EDC and NEN tissue groups did 
not display significantly reduced calcification when compared to the GLUT group.  This 
may be due to the use of formaldehyde, which is part of the same family of chemicals as 
glutaraldehyde and reacts with amine groups in an identical manner.  These crosslinks 
may aggravate the calcification of BHV tissues in a similar manner to glutaraldehyde 
contributing to the calcification of EDC and NEN tissues.  There was also no observed 
difference between NEN and EDC tissue groups suggesting that neomycin does not affect 
the calcification of cusp tissue.  This is consistent with previous data, which 
demonstrated that neomycin does not affect the calcification of EDC/NHS crosslinked 
tissue when used with glutaraldehyde [133]. 
The calcium to phosphorus molar ratios observed for all tissue groups were 
comparable to those found in explanted BHV tissue, suggesting similar progression of 
mineralization in both models [147].  The observed Ca:P molar ratios for all groups were 
also close approximations of the molar ratio for hydroxyapatite, which is a known player 
in BHV calcification [78,79,147].  Similar progression of calcification was also viewed 
using histology, which noted no obvious differences in the morphology of calcified 
regions.  The observed ratio values were slightly lower than the known ratio for 
hydroxyapatite and may indicate increased proportions of dicalcium phosphate dihydrate 
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and octacalcium phosphate.  These are precursors to hydroxyapatite that have been 
documented in calcified BHV tissues [147]. 
It has previously been hypothesized that GAGs may, in some way, function to 
inhibit BHV calcification and various studies have provided evidence to support this 
claim [75,86-88].  It has previously been demonstrated that the removal of GAGs leads to 
heightened levels of calcification [86].  Likewise, various methods of covalent GAG 
binding have reduced calcification [87,88].  NEN tissues were found to fully preserve 
GAGs during rat subdermal implantation; however, no reduction in calcification was 
observed.  This again may be due to the role of formaldehyde crosslinks in EDC and 
NEN tissue calcification.  These crosslinks may exacerbate tissue calcification to such a 
degree that any inhibitory effects offered by GAG preservation are negated. 
 
5.10. Tissue Biomechanics 
Tissue stiffness and extensibility were analyzed using uniaxial tensile testing 
since they may have direct implications on stress levels and the amount of shock loading 
experienced by BHV cusp tissue.  Stiffness increase in cusp tissue is undesirable and has 
been correlated with increased mechanical damage and lower BHV lifespan.  The initial 
generation of BHVs used high-pressure fixation to achieve proper coaptation and 
aesthetic appeal.  These valves had excessively stiff cusps and suffered from far inferior 
durability when compared to later models [71].  Dermal collagen stiffness has been found 
to rise with age and has also been proposed to affect heart valve cusp tissue [13,148].  
This may further provide a correlation between stiffness and failure as incidences of 
native heart increase valve disease increase with age [5].   
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Glutaraldehyde treatment is known to cause an undesirable stiffness increase and 
GLUT tissues were found to display a significantly higher stiffness than FRESH on all 
accounts [152].  NEN tissue was significantly less stiff than GLUT for both directions in 
the high-end response region.  The high-end response in the radial direction was a close 
approximation of natural stiffness, which is promising since cusp tissue experiences the 
greatest amount of deformation in the radial direction.  On the other hand, cusp tissue 
experiences the highest amount of tension in the circumferential direction so a reduction 
of high-end stiffness in this direction may be equally beneficial.  NEN tissues did not 
experience the same excessive stiffness increase that was observed in NEG tissues [UD].  
This is most likely due to storage in formaldehyde, which was previously shown to better 
preserve tissue compliance than glutaraldehyde [143]. 
Decreasing extensibility may also be related to failure and, like increased 
stiffness, has also been found to occur with age in native valves [13,149].  Decreased 
extensibility is also a result of elastin damage, which has been hypothesized to be a 
possible contributor to BHV failure [150].  Finally, decreased extensibility has also been 
documented in failed BHV explants [19,151].  When compared to FRESH tissue, GLUT 
tissues demonstrated a significant decrease in extensibility in the circumferential 
direction as observed previously [152].  All groups that utilized EDC/NHS crosslinking 
performed better by demonstrating significantly higher extensibility than GLUT in both 
directions and higher than FRESH in the radial direction.  Also, the circumferential 
extensibility for all EDC/NHS crosslinked groups was measured to be no different than 
FRESH.  This is consistent with previous data that also demonstrated EDC/NHS 
crosslinked tissues were more extensible than untreated tissues [115]. 
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The differences in the mechanical properties of EDC/NHS crosslinked tissue from 
GLUT and FRESH tissues may be explained by a single phenomenon.  Bond formation 
during carbodiimide crosslinking may cause the tissue to shrink offering an explanation 
for increased extensibility as well as reduced high-end stiffness.  Tissue shrinkage after 
fixation would cause the initial length measurement used in strain calculations to be 
smaller.  Therefore, if two samples of similar size, one sample that underwent shrinkage 
and a one that did not, were measured for extensibility at a common final length, the 
resulting strain and extensibility would be larger for the tissue that underwent shrinkage.  
This may also provide an explanation of the reduction in high-end stiffness since tissue 
shrinkage may also cause collagen molecules to crimp or fold.  When tension reaches the 
high-end response, collagen will not be fully unfolded resulting in a lower stiffness as 
collagen straightens and becomes more taut.  Altered stiffness response may also simply 
be due to differences in ECM microarchitecture, caused by differing crosslinking 
chemistries. 
The third response region that was demonstrated on the stress-strain curve may be 
due to the formation of collagen-GAG crosslinks.  Evidence for these crosslinks was 
given by GAG preservation data, and would be a cause for a unique strain response under 
tension.  Since GAGs have little resistance to tensile force, this would only be viewed 
under low tissue loads.  This would account for the appearance of this unique response in 
the lower stiffnesses of the radial direction.   
Since tissue dimensions were not studied before and after fixation, talk of tissue 
shrinkage is all conjecture.  The effects of observed extensibility and stiffness changes on 
BHV tissue durability are also not known, and cyclic fatigue or full-scale implantation 
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models would be needed to study this.  The effect of strain rate was also not investigated 
and stress-strain responses were only analyzed at an arbitrary strain rate for relative ease.   
It has previously been demonstrated, however, that the use of differing strain rates up to 
physiological values has no affect on the stress-strain behavior of valve leaflet tissue 
during biaxial tensile testing [129].  The effect of the third-response region is unknown, 
and further study on all mechanical responses from biaxial mechanical testing or flexural 
testing may be warranted.  Lastly, the effects of GAG preservation by the NEN group on 
tissue biomechanics have also not been elucidated and deserve further investigation. 
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6. CONCLUSIONS 
The current average lifespan of implanted BHVs is inadequate in many cases, 
causing contraindication of implantation, undesirable reoperation and even catastrophic 
failure.  Increasing BHV durability will not only improve the quality of life for BHV 
recipients, but also open the door for more patients to become suitable candidates for 
BHV replacement.  In order to accomplish this, the foremost causes of BHV failure need 
to be addressed.  It has been determined that structural dysfunction due to the 
accumulation of collagen damage is the primary cause of BHV failure, with calcification 
being a common co-contributor.  Current standard fixation methods, using 
glutaraldehyde, may facilitate these modes of failure.  Therefore, development of an 
alternative fixation method may avoid the drawbacks of glutaraldehyde treatment, 
yielding tissues with better properties that will increase the lifespan of BHVs. 
Glycosaminoglycans are large, hydrated molecules that are present within the 
specialized tissue layers of bioprosthetic heart valve tissue.  The functions of these 
molecules may be vital to preservation of proper tissue biomechanics and, consequently, 
their loss may facilitate premature BHV failure.  GLUT tissues were demonstrated to 
experience GAG loss when subjected to enzymatic degradation, rat subdermal 
implantation, and storage.  EDC crosslinking enables the crosslinking of GAGs and 
reduced losses due to enzymatic degradation and storage.  However, protection against 
GAG loss was incomplete and further protection against enzymatic degradation was 
required.  The use of neomycin in NEN treated tissues drastically improved resistance to 
GAG loss, showing full preservation during enzymatic degradation, rat subdermal 
implantation, and six months of storage. 
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GAG preservation may be important, but preservation of collagen integrity is the 
ultimate goal.  Neomycin was also demonstrated to improve both the collagen and elastin 
stability of carbodiimide crosslinked tissue.  The NEN group displayed superior collagen 
and elastin stability compared to EDC and was also a comparable match for GLUT.  The 
degree of crosslinking for NEN tissues was also found to be sufficient.  The calcification 
potential of NEN tissues was not determined to be significantly different from GLUT 
tissues, and progression of tissue mineralization appeared to be identical for both groups. 
This is thought to be due to the similar crosslinking mechanisms of formaldehyde and 
glutaraldehyde.   
On the other hand, analysis of biomechanics demonstrated clear differentiation in 
responses between NEN and GLUT groups.  GLUT tissues experienced an increase in 
stiffness during fixation and were the stiffest tissues on average.  A reduction in 
extensibility was also observed in the GLUT group.  NEN tissues were measured to be 
less stiff than GLUT on some accounts and were never found to be statistically stiffer.  
NEN tissues also demonstrated vastly improved extensibility over GLUT tissues and 
were even statistically higher than FRESH tissue in the radial direction.   
We have demonstrated, that NEN tissues offer superior GAG preservation while 
still providing the necessary stability for structural ECM components.  NEN fixation was 
not successful at reducing the calcification potential of cusp tissue, but yielded tissues 
improved compliance and extensibility.  NEN fixation, and its associated GAG 
preservation, may improve valve biomechanics and slow the onset of collagen damage.  
As a result, the rate of structural degradation may be reduced resulting in improved 
durability for BHV tissues. 
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7. FUTURE RECOMMENDATIONS 
GAGs were demonstrated to be preserved using NEN fixation, but the effects of 
their preservation were not investigated.  Analysis of valve biomechanics with and 
without selective GAG removal could help reveal this.  Any effects cause by longer 
storage periods should also be studied as valves may be stored clinically for up to three 
years.  EDC and NHS utilize the carboxyl groups on GAGs to form the crosslinks that aid 
in preservation.  However, these same groups are necessary to retain the hydrophilic 
properties of GAGs.  Effects on tissue hydration should be studied along with any 
associated changes this my cause to tissue biomechanics. 
Since formaldehyde is suspected in the calcification experienced by the NEN 
group, storage in an alternative reagent should be investigated.  However, if formalin 
storage is still determined to be favored, the use of anti-calcification treatments could also 
be studied.  Specific attention could also be paid to the areas in which calcification occur.  
As GAGs have been associated with possible prevention of calcification, specific tissue 
layers may be more resistant to calcification than others.  Other segments of BHV tissue, 
such as the aortic wall, should also be tested for calcification potential. 
Further exploration into the mechanisms for the reduced stiffness and increased 
extensibility is needed.  Tissue dimensions should be measured before and after fixation 
to determine the legitimacy of the tissue shrinkage hypothesis.  Further research into the 
effects of NEN fixation should also be performed including flexural testing, biaxial 
tensile testing, and cyclic mechanical fatigue testing.  Changes to valve biomechanics that 
may occur during storage or fatigue should also be assessed.  Lastly, these enhanced 
biomechanical studies should also include studies into the effects of GAG preservation. 
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